|
ALLERGY
|
PAL1 |
THE IMPACT OF THE RX-TO-OTC SWITCH OF LORATADINE
AND CHANGES IN PRESCRIPTION DRUG BENEFITS ON UTILIZATION AND COST OF
THERAPY
Sullivan P1, Nair KV1, Patel BV2
1 University of Colorado, Denver, CO, USA; 2
MedImpact Healthcare Systems, Inc, San Diego, CA, USA |
|
PAL2 |
PATIENT PERCEPTIONS REGARDING THE USE OF
OVER-THE-COUNTER CLARITIN
Nair KV, Sullivan P
University of Colorado, Denver, CO, USA |
|
PAL3 |
WILLINGNESS TO PAY FOR INTRANASAL CORTICOSTEROID
THERAPY: THE IMPORTANCE OF SENSORY ATTRIBUTES
Kleinman L1, Shah SR2, Mahadevia PJ3,
O'Dowd L4, Leibman C4
1 MEDTAP International, Inc, Seattle, WA, USA; 2
Collegeville Professional Center, Collegeville, PA, USA; 3
AMGEN, Inc, Washington, DC, USA; 4 AstraZeneca LP,
Wilmington, DE, USA |
ARTHRITIS-Osteoarthritis
|
PAR1 |
WITHDRAWN |
|
PAR2 |
THE IMPACT OF SPECIALTY CARE ON THE UTILIZATION
OF NEW DRUGS: THE CASE OF COX-2 SELECTIVE INHIBITORS
De Smet BD, Bernstein SJ, Fendrick AM, Stevenson JG
The University of Michigan Health System, Ann Arbor, MI, USA |
|
PAR3 |
TESTING THE BMJ CHECKLIST AS A QUALITY ASSESSMENT
TOOL FOR ECONOMIC EVALUATIONS
Drummond M1, Neumann P2, Risebrough NA3,
Lising A4, Mittmann N3, Niculescu L5
1 University of York, York, United Kingdom; 2
Harvard University, Boston, MA, USA; 3 University of
Toronto, Toronto, ON, Canada; 4 Dymaxium Inc, Toronto, ON,
Canada; 5 Pfizer Inc, New York, NY, USA |
ARTHRITIS-Other
|
PAR4 |
A REVIEW OF TOTAL COST BURDEN OF FIBROMYALGIA
Larsen T1, Patel A2, Coombs J1
1 Pfizer, Ann Arbor, MI, USA; 2 University of
Michigan, Ann Arbor, MI, USA |
|
PAR5 |
DEVELOPMENT OF BENCHMARK METHODOLOGY TO IDENTIFY
GOUT PATIENTS AND GOUT ATTACKS FROM A RETROSPECTIVE DATABASE ANALYSIS
Brewer K1, Yang W1, Sarawate CS1,
Griffith C2, Bakst A2
1 HealthCore, Inc, Wilmington, DE, USA; 2 TAP
Pharmaceuticals, Inc, Lake Forest, IL, USA |
ARTHRITIS-Rheumatoid
Arthritis
|
PAR6 |
HEALTH CARE UTILIZATION AND DIRECT MEDICAL COSTS
IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN DEVELOPING COUNTRY
Soriano ER1, Diaz J2,
Devoto FM3, Imamura P2, Catoggio L1
1 Hospital Italiano de Buenos Aires and Fundación Pedro M.
Catoggio, Buenos Aires, Buenos Aires, Argentina; 2 Hospital
Italiano de Buenos Aires, Buenos Aires, Buenos Aires, Argentina;
3 Pfizer, Buenos Aires, Argentina |
|
PAR7 |
SURVEY OF CURRENT TREATMENT PRACTICES OF
RHEUMATOLOGISTS IN PRESCRIBING TUMOR NECROSIS FACTOR INHIBITORS IN
PATIENTS WITH RHEUMATOID ARTHRITIS
Kamal KM, Madhavan SM, Hornsby JAA
West Virginia University, Morgantown, WV, USA |
|
PAR8 |
ALTERNATIVE DECISION ANALYSIS MODELING IN THE
ECONOMIC EVALUATION OF TUMOR NECROSIS FACTOR INHIBITORS IN PATIENTS
WITH RHEUMATOID ARTHRITIS
Kamal KM, Miller LA, Madhavan SM, Kavookjian J
West Virginia University, Morgantown, WV, USA |
|
PAR9 |
EFFECTS OF ADALIMUMAB MONOTHERAPY ON HEALTH
UTILITY AND FATIGUE IN PATIENTS WITH LONG-STANDING, SEVERE RHEUMATOID
ARTHRITIS (RA)
Mittendorf T1, Sterz R2, Greiner W1,
Von der Schulenburg J1, Cifaldi M3, Dietz B2
1 University of Hannover, Hannover, Germany; 2
Abbott GmbH and Co KG, Ludwigshafen, Germany; 3 Abbott
Laboratories, Abbott Park, IL, USA |
|
PAR10 |
SATISFACTION WITH PAIN MEDICATION AND INTENTION
TO COMPLY WITH TREATMENT: A STRUCTURAL EQUATION MODEL IN RHEUMATOID
ARTHRITIS PATIENTS
Evans CJ1,
Horowicz-Mehler N1, Crawford B1,
Mertzanis P1, Pena BM2, Mayne T2
1 Mapi Values, Boston, MA, USA; 2 Pfizer, Inc,
New York, NY, USA |
|
PAR11 |
THE IMPACT OF DEPRESSION ON RHEUMATOID ARTHRITIS
PATIENT QUALITY OF LIFE
Zhang L, Nichol MB
University of Southern California, School of Pharmacy, Los Angeles,
CA, USA |
|
PAR12 |
ABATACEPT (CTLA4IG) IN COMBINATION WITH
METHOTREXATE DEMONSTRATES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED
OUTCOMES OVER TWO YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH
INADEQUATE RESPONSE TO METHOTREXATE
Li T, Maclean R, Nuamah I, Becker J
Bristol-Myers Squibb, Princeton, NJ, USA |
CANCER
|
PCN1 |
META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF
SCREENING TESTS FOR COLORECTAL CANCER
Slivinskas JC1, Gagnon YM1,
Levy AR2, Enns RA3
1 Oxford Outcomes, Vancouver, BC, Canada; 2
University of British Columbia, Vancouver, BC, Canada; 3
St. Paul's Hospital, UBC, Vancouver, BC, Canada |
|
PCN2 |
SURVIVAL ANALYSIS OF PAIN RELIEF PROVIDED BY
DOXEPIN ORAL RINSE FOR ORAL MUCOSITIS PATIENTS
Epstein JD1, Epstein JB2, Epstein MS3,
Oien HJ4, Truelove EL5
1 University of Southern California, Los Angeles, CA, USA;
2 University of Illinois, Chicago, IL, USA; 3
Fred Hutchison Cancer Research Center, Seattle, WA, USA; 4
Private General Dental Practice, Tualatin, OR, USA; 5
University of Washington, Seattle, WA, USA |
|
PCN3 |
TIME TO CANCER DIAGNOSIS (TDX
) IN YOUNG AMERICANS DEPENDS ON TYPE OF CANCER AND HEALTH
INSURANCE STATUS
Martin SK1, Ulrich C2, Munsell M3,
Taylor S3, Lange G3, Bleyer A3
1 Baylor College of Medicine, Houston, TX, USA; 2
University of Rochester, Rochester, NY, USA; 3 The
University of Texas MD Anderson Cancer Center, Houston, TX, USA |
|
PCN4 |
ECONOMIC EVALUATION OF INTRAVENOUS (IV)
ZOLEDRONIC ACID VS. OTHER IV BISPHOSPHONATES IN THE PREVENTION OF BONE
COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES: A UK
BUDGET IMPACT ANALYSIS
Botteman M1, Aapro M2, Hay JW3,
Stephens J1, Brandman J4
1 PharMerit North America, Bethesda, MD, USA; 2
Clinique de Genolier, Genolier, Switzerland; 3 University
of Southern California, Los Angeles, CA, USA; 4 Novartis
Pharmaceutical Corporation, Florham Park, NJ, USA |
|
PCN5 |
BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV)
ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE
PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE
METASTASES: A UK NHS PERSPECTIVE
Botteman M1, Aapro M2, Stephens J1,
Hay JW3, Brandman J4
1 PharMerit North America, Bethesda, MD, USA; 2
Clinique de Genolier, Genolier, Switzerland; 3 University
of Southern California, Los Angeles, CA, USA; 4 Novartis
Pharmaceutical Corporation, Florham Park, NJ, USA |
|
PCN6 |
ECONOMICS OF PRIMARY & SECONDARY BREAST CANCER
PREVENTIVE STRATEGIES: A DECISION MODEL
Borker RD1,
Madhavan SM2, Scott V2
1 GlaxoSmithKline, Research Triangle Park, NC, USA; 2
West Virginia University, Morgantown, WV, USA |
|
PCN7 |
THE COST-EFFECTIVENESS OF CAPECITABINE AS
ADJUVANT ORAL CHEMOTHERAPY FOR DUKE’S C COLON CANCER
Garrison L1, Patel KK2, Sengupta N3,
Green J2, Best JH1, Ramsey S4
1 University of Washington, Seattle, WA, USA; 2
Hoffmann-La Roche, Nutley, NJ, USA; 3 Roche Laboratories,
Nutley, NJ, USA; 4 Fred Hutchinson Cancer Research Center,
Seattle, WA, USA |
|
PCN8 |
THE COST-EFFECTIVENESS OF PROSTATE-SPECIFIC
ANTIGEN SCREENING FOR PROSTATE CANCER DETECTION
Tencer T, Hay JW
University of Southern California, Los Angeles, CA, USA |
|
PCN9 |
THE COST-EFFECTIVENESS OF HERCEPTIN® IN ADJUVANT
SETTING: THE HERA TRIAL
Neyt M1, Cocquyt V2, Albrecht J1
1 Ghent University, Gent, Belgium; 2 University
Hospital Gent, Gent, Belgium |
|
PCN10 |
ECONOMIC IMPACT OF PROSTATE-SPECIFIC ANTIGEN
DOUBLING TIME IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER
Mulani P1, Botteman M2, Hay JW3,
Cifaldi M1
1 Abbott Laboratories, Abbott Park, IL, USA; 2
PharMerit North America, Bethesda, MD, USA; 3 University of
Southern California, Los Angeles, CA, USA |
|
PCN11 |
THE COST OF CANCER IN KOREA: 1999 - 2003
Jung YH, Ko S
Korea Institute for Health and Social Affairs, Seoul, South Korea |
|
PCN12 |
ESTIMATING COSTS OF UNCONTROLLED
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING AMONG WORKING-AGE CANCER
PATIENTS
Shih YCT1, Han S2, Zhao L1,
Elting LS1
1 University of Texas MD Anderson Cancer Center, Houston,
TX, USA; 2 Rice University, Houston, TX, USA |
|
PCN13 |
SURVIVAL AND COST FOLLOWING BREAST CANCER
RECURRENCE: ESTIMATES FROM SEER-MEDICARE DATA
Thompson D1, O'Sullivan AK1, Stokes M1,
Montoya E1, Earle C2, Winer EP2,
Kulig K3, Weinstein M4
1 Innovus Research, Inc, Medford, MA, USA; 2
Dana-Farber Cancer Institute, Boston, MA, USA; 3 Pfizer
Inc, New York, NY, USA; 4 Harvard School of Public Health &
Innovus Research, Inc, Boston, MA, USA |
|
PCN14 |
IS COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE
COST-EFFECTIVE COMPARED WITH COMBINED ANDROGEN BLOCKADE WITH
FLUTAMIDE?
Ramsey S1, Veenstra DL2, Clarke L3,
Penson D4, Gandhi S5, Hirsch M5
1 Fred Hutchinson Cancer Research Center, Seattle, WA, USA;
2 University of Washington, Seattle, WA, USA; 3
Cornerstone Northwest, Lynden, WA, USA; 4 University of
Southern California, Los Angeles, CA, USA; 5 AstraZeneca,
Wilmington, DE, USA |
|
PCN15 |
RESOURCE UTILIZATION AMONG PROSTATE CANCER
PATIENTS WITH BONE PAIN
Kurth H1, McKiernan J2, Thomas SK3,
Bentkover JD1
1 Innovative Health Solutions, Brookline, MA, USA; 2
Columbia Presbyterian, New York, NY, USA; 3 Novartis
Pharmaceuticals Corp, East Hanover, NJ, USA |
|
PCN16 |
THE CLINICAL OUTCOMES AND COSTS OF TREATING
ONCOLOGY PATIENTS FOR SEVERE SEPSIS
King KM, Langley GD, Canada TW, Botz GH, Wu C, Walker WR
The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA |
|
PCN17 |
ASSESSMENT OF BREAST CANCER KNOWLEDGE, SCREENING
BEHAVIOR, RISK PERCEPTIONS, AND WILLINGNESS TO CONSUME CHEMOPREVENTIVE
AGENT IN WOMEN IN THE WEST VIRGINIA MEDICAID PROGRAM (WVMP)
Borker RD1,
Madhavan SM2, Higa G2
1 GlaxoSmithKline, RTP, NC, USA; 2 West Virginia
University, Morgantown, WV, USA |
|
PCN18 |
OPIOID USE IN A LARGE NATIONAL HOSPICE
POPULATION: EXAMINATION OF CANCER VERSUS NON-CANCER PATIENTS
Weston C1,
Poston S1, Pizzi L1, Goldfarb N1,
Sikirica V2, Reifsnyder J3, Maxwell TL3
1 Jefferson Medical College, Philadelphia, PA, USA; 2
Janssen Medical Affairs, L.L.C, Titusville, NJ, USA; 3
ExcelleRx, Inc, Philadelphia, PA, USA |
|
PCN19 |
VARIATIONS IN INPATIENT PROSTATE CANCER TREATMENT
IN FLORIDA
Campbell ES, Grant S
Florida A&M University, Tallahassee, FL, USA |
|
PCN20 |
A SYSTEMATIC REVIEW OF PHYSICIAN KNOWLEDGE AND
PRACTICE PATTERNS REGARDING COLORECTAL CANCER SCREENING
Khanna R, Kavookjian J
West Virginia University, Morgantown, WV, USA |
|
PCN21 |
RETRANSFORMATION OF ESTIMATED LOG-TRANSFORMED
COSTS WHEN THE ERRORS PRESENT HETEROSKEDASTICITY
Baser O
Medstat, Inc, Ann Arbor, MI, USA |
|
PCN22 |
ESTIMATION OF CENSORED MEDICAL COUNT DATA
Baser O
Medstat, Inc, Ann Arbor, MI, USA |
|
PCN23 |
RELIABILITY OF SPANISH-LANGUAGE HUI MEASUREMENTS
IN SURVIVORS OF CANCER IN CHILDHOOD: AGREEMENT BETWEEN PATIENTS,
PARENTS, AND PHYSICIANS
Talsma D1,
Fu L2, Furlong W1, Barr R1
1 McMaster University, Hamilton, ON, Canada; 2
Hospital Materno Infantil/Hospital Escuela, Tegucigalpa, Honduras,
Honduras |
|
PCN24 |
HANDLING MISSING PATIENT REPORTED OUTCOMES (PRO)
DATA FOR PREMATURE WITHDRAWALS FROM CLINICAL TRIALS OF SEVERE DISEASES
Crawford B1, Massaro J2, Dhawan R3,
Gupta S4
1 Mapi Values, Boston, MA, USA; 2 Boston
University, Boston, MA, USA; 3 Johnson & Johnson
Pharmaceutical Services, Raritan, NJ, USA; 4 Millennium
Pharmaceuticals, Inc, Cambridge, MA, USA |
|
PCN25 |
RELIABILITY AND VALIDITY OF BRAZILIAN PORTUGUESE
HEALTH UTILITIES INDEX (HUI) QUESTIONNAIRES FOR ASSESSING THE HEALTH
STATUS OF SURVIVORS OF CHILDHOOD CANCER
Horsman JR1, Shimoda S2, Furlong W1,
Barr RD3
1 McMaster University, Hamilton, ON, Canada; 2
Centro de Tratamento e Pesquisa Hospital do Cancer, Sao Paulo, SP,
Brazil; 3 Hamilton Health Sciences, McMaster University,
Hamilton, ON, Canada |
|
PCN26 |
DERIVING A PREFERENCE-BASED INDEX FROM THE MD
ANDERSON SYMPTOM INVENTORY IN CANCER PATIENTS
Shih YCT, Cantor SB, Wang XS, Cleeland CS
University of Texas MD Anderson Cancer Center, Houston, TX, USA |
|
PCN27 |
INCONGRUENT DEFINITIONS OF RISK AND UNCERTAINTY
AMONG CLINICAL ONCOLOGISTS AND ITS IMPLICATIONS FOR DECISION MAKING
Molnar R1, Carrera P2, Terris DD2,
Bridges JFP2
1 Case School of Medicine, Cleveland, OH, USA; 2
University of Heidelberg, Heidelberg, Baden Wuerttembe, Germany |
DIABETES
|
PDB1 |
PREVALENCE OF CO-MORBID CONDITIONS AND
CONCOMITANT MEDICATION USE AMONG TYPE-2 DIABETES PATIENTS IN A STATE
MEDICAID POPULATION
Kavookjian J1, Mody R1, Kalsekar I2,
Iyer S3, Rajagopalan R3, Pawar V1
1 West Virginia University, Morgantown, WV, USA; 2
Butler University, Indianapolis, IN, USA; 3 Takeda
Pharmaceuticals North America, Inc, Lincolnshire, IL, USA |
|
PDB2 |
IMPACT OF DEPRESSION ON INCIDENCE OF TYPE-2
DIABETES IN A STATE MEDICAID POPULATION
Kalsekar I1, Madhavan SM2, Amonkar M3,
Makela E2, Scott V2, Douglas S2
1 Butler University, Indianapolis, IN, USA; 2
West Virginia University, Morgantown, WV, USA; 3
GlaxoSmithKline, Collegeville, PA, USA |
|
PDB3 |
EARLY DETECTION OF CVD BY MYOCARDIAL PERFUSION
IMAGING IN ASYMPTOMATIC PATIENTS WITH DIABETES
Papatheofanis FJ
University of California, San Diego, San Diego, CA, USA |
|
PDB4 |
GLYCEMIC RESPONSE TO PIOGLITAZONE THERAPY IN
AFRICAN-AMERICAN AND LATINO PATIENTS WITH TYPE-2 DIABETES
Rajagopalan R, Naughten P, Vallarino C
Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA |
|
PDB5 |
CAN USE OF GLITAZONES REDUCE THE RISK OF
ALZHEIMER’S DISEASE IN PATIENTS WITH DIABETES?
Yu AP1, Lee LJ1, Yu YF2,
Nichol MB3
1 University of Southern California, Los Angeles, CA, USA;
2 HealthCore, Inc, Wilmington, DE, USA; 3
University of Southern California, School of Pharmacy, Los Angeles,
CA, USA |
|
PDB6 |
TREATMENT PATTERNS IN MANAGEMENT OF TYPE-2
DIABETES WITH CONCURRING COMORBIDITIES
Lipskiy N, Kress A
Surveillance Data Inc, Plymouth Meeting, PA, USA |
|
PDB7 |
CLINICAL JUDGMENT OF DRUG THERAPY FOR TYPE-2
DIABETES PATIENTS AND RESULTS OF HBA1C TESTS
Lipskiy N
Surveillance Data Inc, Plymouth Meeting, PA, USA |
|
PDB8 |
PREVALENCE OF DIABETES MELLITUS AND TREATMENT
PATTERNS BASED ON CLASSIFICATION OF BODY MASS INDEX AMONG ADULTS
Suh DC, Shin HC, Vo L, Valiyeva E, Barone JA
Rutgers University, Piscataway, NJ, USA |
|
PDB9 |
FACTORS ASSOCIATED WITH A LOWER GLYCOSYLATED
HEMOGLOBIN A1C (A1C) IN A DIABETIC LATINO POPULATION
Aranda GA, Bonnet PO, Johnson KA
University of Southern California, Los Angeles, CA, USA |
|
PDB10 |
ECONOMIC BURDEN OF DIABETIC RETINOPATHY IN
FLORIDA: A PILOT STUDY EXPLORING THE AMOUNT SPENT USING PRINCIPLE
DIAGNOSES
Batiste L, Xiao H
Florida A & M University, Tallahassee, FL, USA |
|
PDB11 |
EVALUATION OF THE CLINICAL OUTCOME AND FINANCIAL
COSTS OF DELAYING THE ONSET OF FRANK TYPE-2 DIABETES
McEwan P1, Peters JR2, Currie CJ1
1 Cardiff University, Cardiff, United Kingdom; 2
University Hospital of Wales, Cardiff, United Kingdom |
|
PDB12 |
EFFECT OF GLYCEMIC CONTROL ON HEALTH CARE COSTS
Secnik K1, Oglesby A1, Shetty S2,
Lage MJ3
1 Eli Lilly and Company, Indianapolis, IN, USA; 2
i3 Magnifi, Eden Prairie, MN, USA; 3 HealthMetrics Outcomes
Research, Groton, CT, USA |
|
PDB13 |
COST OF DIABETES COMPLICATIONS IN FRANCE,
GERMANY, ITALY AND SPAIN
Palmer AJ1, Ray JA1, Roze S1,
Valentine WJ1, Secnik K2, Oglesby A2
1 CORE - Center for Outcomes Research, Binningen, Basel,
Switzerland; 2 Eli Lilly and Company, Indianapolis, IN, USA |
|
PDB14 |
ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS
THERAPY VERSUS NEUTRAL PROTAMINE HAGEDORN-BASED BASAL/BOLUS THERAPY
FOR TYPE-1 DIABETES IN A DUTCH SETTING
Roze S1, Wittrup-Jensen K2, Valentine WJ1,
Palmer AJ1
1 CORE - Center for Outcomes Research, Binningen, Basel,
Switzerland; 2 Novo Nordisk A/S, Bagsvaerd, Denmark |
|
PDB15 |
DIABETIC RETINOPATHY MODELING: A
COST-EFFECTIVENESS OF VARYING SCREENING INTERVALS IN TYPE-2 DIABETES
MELLITUS IN THAILAND
Pornpinatepong S1,
Chaiyakunapruk N2, Thavorncharoensap M1
1 Mahidol University, Bangkok, Bangkok, Thailand; 2
Naresuan University, Phitsanulok, Phitsanulok, Thailand |
|
PDB16 |
THE ASSOCIATION BETWEEN DIABETES RELATED MEDICAL
COSTS AND GLYCEMIC CONTROL: A LONGITUDINAL ANALYSIS
Oglesby A1, Secnik K1, Barron JJ2,
Al-Zakwani IS2, Lage MJ3
1 Eli Lilly and Company, Indianapolis, IN, USA; 2
HealthCore, Wilmington, DE, USA; 3 HealthMetrics Outcomes
Research, Groton, CT, USA |
|
PDB17 |
BURDEN OF ILLNESS ASSOCIATED WITH SYMPTOMS OF
DIABETIC PERIPHERAL NEUROPATHY AND DIABETIC RETINOPATHY
Candrilli SD1, Davis KL1, Kan HJ2,
Lucero MA1, Covington MT2
1 RTI Health Solutions, Research Triangle Park, NC, USA;
2 Eli Lilly and Company, Indianapolis, IN, USA |
|
PDB18 |
ECONOMIC EVALUATION OF DRUG THERAPY AMONG
DIABETES MILLITUS PATIENTS IN OLABISI ONABANJO UNIVERSITY TEACHING
HOSPITAL, SAGAMU, OGUN STATE, NIGERIA
Suleiman IA1, Oloyede FF2
1 University of Lagos, Lagos, Nigeria; 2 Olabisi
Onabanjo University, Sagamu, Nigeria |
|
PDB19 |
COLLECTION OF COST DATA FOR DIABETES
COMPLICATIONS IN CANADA AND AUSTRALIA
Palmer AJ1, Ray JA1, Roze S1,
Valentine WJ1, Secnik K2, Oglesby A2
1 CORE - Center for Outcomes Research, Binningen, Basel,
Switzerland; 2 Eli Lilly and Company, Indianapolis, IN, USA |
|
PDB20 |
COMPARISON OF THE COST TO REACH A1C TARGETS IN
PATIENTS WITH TYPE-2 DIABETES MELLITUS ON ORAL ANTIDIABETIC AGENTS AND
EITHER BIPHASIC INSULIN ASPART 70/30 OR INSULIN GLARGINE
Cobden D1, Allen E1, Botteman M2
1 Novo Nordisk Inc, Princeton, NJ, USA; 2
PharMerit, Bethesda, MD, USA |
|
PDB21 |
HEALTH CARE RESOURCE UTILIZATION AND COST IN
TYPE-2 DIABETES PATIENTS RECEIVING COMBINATION SULFONYLUREA (SU) AND
ROSIGLITAZONE (RSG): THE RESULT TRIAL
Herman WH1,
Horblyuk R2, Arondekar B2, O'Neill MC3,
Kravitz B3, Heise MA3, Freed MI3
1 Michigan Diabetes Research and Training Center, Ann
Arbor, MI, USA; 2 GlaxoSmithKline, Philadelphia, PA, USA;
3 GlaxoSmithKline, King of Prussia, PA, USA |
|
PDB22 |
LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART
VERSUS SOLUBLE HUMAN INSULIN IN PATIENTS WITH TYPE 1 DIABETES IN THE
UNITED KINGDOM
Minshall ME1, Twena NS2, Nicklasson L3,
Roze S4
1 CORE-Center for Outcomes Research, Fishers, IN, USA;
2 Novo Nordisk Ltd, Crawley, West Sussex, United Kingdom; 3
Novo Nordisk Inc, Princeton, NJ, USA; 4 CORE-Center for
Outcomes Research, Binningen, Basel, Switzerland |
|
PDB23 |
EVALUATION OF THE IMPACT ON THE EQ5DINDEX
(HEATH-RELATED UTILITY) OF CONVERSION TO INSULIN GLARGINE (LANTUS)
FOLLOWING FAILURE ON ORAL AGENTS IN PEOPLE WITH TYPE-2 DIABETES:
INTERIM ANALYSIS
Peters JR1, Morrissey M2, Morgan CL2,
Piper E3, Sharplin P4, Currie CJ2
1 University Hospital of Wales, Cardiff, United Kingdom;
2 Cardiff University, Cardiff, United Kingdom; 3
Sanofi-Aventis, Kent, United Kingdom; 4 Sanofi-Aventis,
Auckland, New Zealand |
|
PDB24 |
ECONOMIC IMPACT OF CARDIOVASCULAR CO-MORBIDITY IN
PATIENTS WITH TYPE-2 DIABETES
Mody R1, Kalsekar I2, Kavookjian J1,
Iyer S3, Rajagopalan R3, Pawar V1
1 West Virginia University, Morgantown, WV, USA; 2
Butler University, Indianapolis, IN, USA; 3 Takeda
Pharmaceuticals North America, Inc, Lincolnshire, IL, USA |
|
PDB25 |
DEPRESSION IN PATIENTS WITH TYPE-2 DIABETES:
IMPACT ON UTILIZATION PATTERNS AND ADHERENCE TO ORAL HYPOGLYCEMIC
AGENTS
Kalsekar I1, Madhavan SM2, Amonkar M3,
Douglas S2, Makela E2, Scott V2
1 Butler University, Indianapolis, IN, USA; 2
West Virginia University, Morgantown, WV, USA; 3
GlaxoSmithKline, Collegeville, PA, USA |
|
PDB26 |
BURDEN OF NON-ADHERENCE TO ORAL ANTIDIABETICS
Curkendall S1, Sarocco P2, Goldberg GA3,
Patton MP3
1 Healthcare Data Analysis, Vienna, VA, USA; 2
Sanofi-Aventis US Pharma, Bridgewater, NJ, USA; 3 i3
Magnifi, Reston, VA, USA |
|
PDB27 |
IMPACT OF A DIABETES CARE PROJECT ON MEDICATION
UTILIZATION AND ADHERENCE
Lee K, Sun SX, Matusik M, Bhayani H, Gunderson S, Bertram C
Walgreens Health Initiatives, Deerfield, IL, USA |
|
PDB28 |
AN EVALUATION OF A DISEASE MANAGEMENT PROGRAM FOR
ADULT DIABETICS IN A MEDICAID POPULATION
Yaffe K, Skrepnek GH, Armstrong EP
University of Arizona College of Pharmacy, Tucson, AZ, USA |
|
PDB29 |
THE EFFECT OF INSULIN TREATMENT ON HEALTH CARE
UTILIZATION IN TYPE-II DIABETES
Thiebaud P1, Nichol MB1, Patel BV2
1 University of Southern California, School of Pharmacy,
Los Angeles, CA, USA; 2 MedImpact Healthcare Systems, Inc,
San Diego, CA, USA |
|
PDB30 |
TREATMENT PATTERNS AMONG PATIENTS WITH DIABETES
ON METFORMIN AND SULFONYLUREA COMBINATION THERAPY
Pietri G1, Yin D2, Lyu R2
1 Rutgers University, Piscataway, NJ, USA; 2
Merck & Co., Inc, Whitehouse Station, NJ, USA |
|
PDB31 |
FACTORS ASSOCIATED WITH HEALTH CARE COST SAVING
IN PATIENTS WITH DIABETES TO THE CALIFORNIA MEDICAID POPULATIONS
(MEDI-CAL)
Chaikledkaew U1, Johnson KA2
1 Mahidol University, Payathai, Bangkok, Thailand; 2
University of Southern California, Los Angeles, CA, USA |
|
PDB32 |
THE RELATIONSHIP BETWEEN PATIENT’S TYPE OF
PAYMENT AND PRESCRIPTION DRUG COSTS FOR DIABETIC PATIENTS
Ngorsuraches S1, Sisang T2
1 Prince of Songkla University, Hatyai, Songkla, Thailand;
2 Maharaj Nakorn Sri Thammarat Hospital, Muang, Nakorn Sri
Thamm, Thailand |
|
PDB33 |
PRESCRIBING TRENDS FOR COMBINATION PRODUCTS IN
THE TREATMENT OF TYPE-II DIABETES
Bilek JC1, Carlson A2, Morris LS3
1 University of Minnesota, Minneapolis, MN, USA; 2
Data Intelligence, Eden Prairie, MN, USA; 3 IMS Health,
Plymouth Meeting, PA, USA |
|
PDB34 |
NEEDLESTICK INJURY IN NURSES CARING FOR PATIENTS
WITH DIABETES
Pashos CL1, Nicklasson L2, Lee JM3,
Botteman MF4, Cobden D2
1 Abt Associates Inc, Lexington, MA, USA; 2 Novo
Nordisk Inc, Princeton, NJ, USA; 3 Abt Associates Inc,
Bethesda, MD, USA; 4 PharMerit, Bethesda, MA, USA |
|
PDB35 |
FACTOR ANALYSIS AND PRELIMINARY VALIDATION OF
INSULIN DELIVERY SYSTEM QUESTIONNAIRE
Hayes RP, Lenox SM
Eli Lilly & Company, Indianapolis, IN, USA |
|
PDB36 |
RELIABILITY AND VALIDITY OF THE GENERAL DIABETES
KNOWLEDGE TEST
Wee HL1, Zhang XH1, Tan K2,
Tan HH3, Thumboo J4, Li SC5
1 National University of Singapore, Singapore, Singapore;
2 Diabetic Society of Singapore, Singapore, Singapore;
3 Singhealth Polyclinics, Singapore, Singapore; 4
Singapore General Hospital, Singapore, Singapore; 5
National University Singapore, Singapore, Singapore, Singapore |
|
PDB37 |
HEALTH ECONOMIC COMPARISON OF INSULIN ASPART, A
FAST-ACTING INSULIN ANALOG, VERSUS HUMAN INSULIN AS MEALTIME INSULIN
IN THE TREATMENT OF TYPE-1 DIABETES IN AUSTRIAN, DANISH, DUTCH,
FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH AND SWEDISH SETTINGS
Palmer AJ1, Lammert M2, Minshall M3,
Roze S1, Nicklasson L4, Valentine WJ1
1 CORE-Center for Outcomes Research, Binningen, Basel,
Switzerland; 2 Novo Nordisk A/S, Bagsvaerd, Denmark; 3
CORE - Centre for Outcomes Research, Fishers, IN, USA; 4
Novo Nordisk Inc, Princeton, NJ, USA |
|
PDB38 |
MEASURING THE EFFECT OF THE VARIABILITY OF
INSULIN USE ON HEALTH CARE COSTS IN DIABETES
Curkendall S1, Sarocco P2, Goldberg GA3,
Patton MP3
1 Healthcare Data Analysis, Vienna, VA, USA; 2
Sanofi-Aventis US Pharma, Bridgewater, NJ, USA; 3 i3
Magnifi, Reston, VA, USA |
|
PDB39 |
DEVELOPMENT OF AN INTEGRATED DIABETES DATABASE
ACROSS COMMUNITY CLINICS AND HOSPITALS
Ho MJ1, Sauer B2, Stockdale B1,
Brixner D1
1 University of Utah, Salt Lake City, UT, USA; 2
Veterans Affairs, Salt Lake City, Salt Lake City, UT, USA |
|
PDB40 |
THE USE OF DIABETES PREVENTION PROGRAM RESULTS TO
MODEL COST-EFFECTIVENESS OF THE INTERVENTION IN A MORE GENERALIZED
HYPOTHETICAL POPULATION
Novak S, Lawson K, Wilson J
University of Texas at Austin, Austin, TX, USA |
|
PDB41 |
VALIDATION OF THE GERMAN TRANSLATION OF THE
NORFOLK QOL-DN, NERVE FIBER SPECIFIC QUESTIONNAIRE IN A NATIONAL,
MULTICENTER COST OF ILLNESS STUDY (DIMICO) FOR DIABETIC MICROVASCULAR
COMPLICATIONS IN GERMANY
Vinik EJ1, Paulson J2, Ford-Molvik SL1,
Oglesby A3, Watkins J3, Hayes C3,
Vinik AI1
1 Eastern Virginia Medical School, Norfolk, VA, USA; 2
Center for Pediatric Research, Norfolk, VA, USA; 3 Eli
Lilly and Company, Indianapolis, IN, USA |
|
PDB42 |
ESTIMATING THE EFFECT OF SYMPTOMS OF DIABETIC
PERIPHERAL NEUROPATHY AND DIABETIC RETINOPATHY ON QUALITY-OF-LIFE
USING DATA FROM THE 2001-2002 NATIONAL HEALTH AND NUTRITION
EXAMINATION SURVEY
Davis KL1,
Candrilli SD1, Kan HJ2, Lucero MA1,
Covington MT2
1 RTI Health Solutions, Research Triangle Park, NC, USA;
2 Eli Lilly and Company, Indianapolis, IN, USA |
|
PDB43 |
ASSOCIATIONS AMONG VISUAL IMPAIRMENT, STAGE OF
DIABETIC RETINOPATHY AND QUALITY OF LIFE (EQ-5D)
Smith D1, Johnson E1, Russell A1,
Hazlehurst B1, Muraki C1, Nichols G1,
Kan HJ2, Brown J1
1 Center for Health Research, Kaiser Permanente NW,
Portland, OR, USA; 2 Eli Lilly and Company, Indianapolis,
IN, USA |
|
PDB44 |
IS DIABETES KNOWLEDGE ASSOCIATED WITH
HEALTH-RELATED QUALITY OF LIFE AMONG ENGLISH-SPEAKING SUBJECTS WITH
DIABETES IN SINGAPORE?
Zhang XH1, Wee HL1, Tan K2,
Tan HH3, Thumboo J4, Li SC1
1 National University of Singapore, Singapore, Singapore;
2 Diabetic Society of Singapore, Singapore, Singapore;
3 Singhealth Polyclinics, Singapore, Singapore; 4
Singapore General Hospital, Singapore, Singapore |
|
PDB45 |
QUALITY OF LIFE (SF12), CLINICAL OUTCOMES, AND
COMORBID CONDITIONS IN PATIENTS WITH TYPE-2 DIABETES: A POPULATION
STUDY
Sundaram M, Kavookjian J
West Virginia University, Morgantown, WV, USA |
|
PDB46 |
WILLINGNESS-TO-PAY FOR INHALED INSULIN – A
CANADIAN PERSPECTIVE.
Sadri H
Health Outcome and Pharmacoeconomics Research Centre, Toronto, ON,
Canada |
EAR
|
PER1 |
EVALUATION OF AN OTITIS MEDIA EDUCATION
INTERVENTION IN AN INTEGRATED DELIVERY SYSTEM
Beaton SJ1, Gunter MJ1, Paez KA1,
Chilton L2, Dougherty D3
1 Lovelace Clinic Foundation, Albuquerque, NM, USA; 2
Lovelace Sandia Health System, Albuquerque, NM, USA; 3
Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA |
|
PER2 |
PROCESS EVALUATION OF THE IMPLEMENTATION OF
OTITIS MEDIA GUIDELINES IN AN INTEGRATED DELIVERY SYSTEM
Gunter MJ1, Beaton SJ1, Paez KA1,
Chilton L2, Dougherty D3
1 Lovelace Clinic Foundation, Albuquerque, NM, USA; 2
Lovelace Sandia Health System, Albuquerque, NM, USA; 3
Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA |
EYE
|
PEY1 |
COMORBIDITIES AND INCIDENCE RATE OF GLAUCOMA IN
THE CALIFORNIA MEDICAID POPULATION – A CASE-CONTROL STUDY
Lee LJ1, Yu AP2, Yu YF3,
Nichol MB1
1 University of Southern California, School of Pharmacy,
Los Angeles, CA, USA; 2 University of Southern California,
Los Angeles, CA, USA; 3 HealthCore, Inc, Wilmington, DE,
USA |
|
PEY2 |
CHARACTERIZATION OF THE FREQUENCY AND REASONS FOR
CHANGES IN PHARMACOTHERAPY IN THE TREATMENT OF PRIMARY OPEN-ANGLE
GLAUCOMA, NORMAL TENSION GLAUCOMA, AND OCULAR HYPERTENSION USING
RETROSPECTIVE ANALYSIS OF THE GLASGOW ROYAL INFIRMARY GLAUCOMA
DATABASE
Montgomery D1, Mychaskiw MA2
1 Department of Ophthalmology, Glasgow, Scotland, United
Kingdom; 2 Pfizer, Inc, New York, NY, USA |
|
PEY3 |
REFILL COSTS AND BUDGET IMPACT OF GLAUCOMA LIPID
THERAPY: A RETROSPECTIVE DATABASE ANALYSIS
Walt JG1, Chiang TH1, Guckian A2,
Bennett TM2, Diefenderfer R2
1 Allergan, Inc, Irvine, CA, USA; 2 NDCHealth,
Phoenix, AZ, USA |
|
PEY4 |
A COST-BENEFIT ANALYSIS OF AN APODIZED
DIFFRACTIVE MULTIFOCAL INTRA-OCULAR LENS BASED ON WILLINGNESS-TO-PAY
IN CATARACT PATIENTS
Waycaster C
Alcon Laboratories Inc, Fort Worth, TX, USA |
|
PEY5 |
THE COST-EFFECTIVENESS OF DIFFERENT CASE-FINDING
STRATEGIES FOR DETECTION AND TREATMENT OF OCULAR HYPERTENSION AND
PRIMARY OPEN-ANGLE GLAUCOMA BY THE OPHTHALMOLOGIST
Peeters A1, Schouten J1, Webers C1,
Severens J2, Hendrikse F1, Prins M2
1 Academic Hospital Maastricht, Maastricht, Netherlands;
2 Maastricht University, Maastricht, Netherlands |
|
PEY6 |
MEDICAL CARE COSTS OF PRIMARY OPEN-ANGLE GLAUCOMA
IN THE UNITED STATES: A NATIONAL ESTIMATE USING THE MEDICAL
EXPENDITURE PANEL SURVEY
Mychaskiw MA1, Schwartz GF2
1 Pfizer, Inc, New York, NY, USA; 2 Greater
Baltimore Medical Center, Baltimore, MD, USA |
|
PEY7 |
COST OF GLAUCOMA TO THE CALIFORNIA MEDICAID
(MEDI-CAL) PROGRAM BETWEEN 1995 AND 2002
Lee LJ1, Yu AP1, Yu YF2,
Nichol MB1
1 University of Southern California, School of Pharmacy,
Los Angeles, CA, USA; 2 HealthCore, Inc, Wilmington, DE,
USA |
|
PEY8 |
PATIENT-REPORTED VISUAL FUNCTION IN LOW-VISION
POPULATIONS (NEI-VFQ): AN ANALYSIS WITH COMPARISONS OF READING
PERFORMANCE, CONTRAST SENSITIVITY, SCOTOMA TESTING, AND VISUAL ACUITY
Tencer T1, Chang TS1, Fletcher DC2,
Globe DR1
1 University of Southern California, Los Angeles, CA, USA;
2 Smith-Kettlewell Eye Research Institute, San Francisco,
CA, USA |
GI DISORDERS
|
PGI1 |
PREVALENCE AND RISK FACTORS FOR DIARRHEA AT A
LARGE TERTIARY CARE MEDICAL CENTER
Kachroo S1, Kumar N1, Graham G2,
Gerard L1, Dao T2, Price M2, Dupont H2,
Garey KW1
1 University of Houston, College of Pharmacy, Houston, TX,
USA; 2 St. Luke's Episcopal Health System, Houston, TX, USA |
|
PGI2 |
THE BUDGET IMPACT OF TEGASEROD ON A MANAGED CARE
ORGANIZATION FORMULARY
Bloom MA1, Barghout V2, Kahler KH2,
Bentkover JD1,
Kurth H1, Gralnek IM3, Spiegel B4
1 Innovative Health Solutions, Brookline, MA, USA; 2
Novartis Pharmaceuticals Corp, East Hanover, NJ, USA; 3
David Geffen School of Medicine at UCLA, VA Greater Los Angeles
Healthcare System, CURE Digestive Diseases Research Center, Los
Angeles, CA, USA; 4 Department of Gastroenterology and
Hepatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA,
USA |
|
PGI3 |
THE ECONOMIC IMPLICATIONS OF SOMATROPIN [RDNA
ORIGIN] MANAGEMENT IN PATIENTS WITH SHORT BOWEL SYNDROME
Migliaccio-Walle K, Caro JJ, Möller J
Caro Research, Concord, MA, USA |
|
PGI4 |
THE COST-EFFECTIVENESS OF TWO STRATEGIES FOR
VACCINATING PATIENTS WITH HEPATITIS C VIRUS INFECTION AGAINST
HEPATITIS A AND HEPATITIS B
Jakiche R1, Borrego ME1, Raisch D2,
Gupchup G3, Pai M1, Jakiche A4
1 University of New Mexico, Albuquerque, NM, USA; 2
VA Cooperative Studies Program, Albuquerque, NM, USA; 3
Southern Illinos University Edwardsville, Edwardsville, IL, USA;
4 Albuquerque VA Hospital, Albuquerque, NM, USA |
|
PGI5 |
COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A
(40KD) COMPARED TO LAMIVUDINE FOR THE TREATMENT OF E ANTIGEN NEGATIVE
CHRONIC HEPATITIS B IN THE UK
Veenstra DL1, Sullivan SD1, Lewis G2,
Green J3
1 University of Washington, Seattle, WA, USA; 2
Roche Products Limited, Welwyn Garden City, Herts, United Kingdom;
3 Hoffmann-La Roche, Nutley, NJ, USA |
|
PGI6 |
UTILIZATION, RE-TREATMENT, AND COST OF DIFFERING
LENGTHS OF H. PYLORI TREATMENT REGIMENS FROM US HEALTH CARE CLAIMS
DATABASES
Orsini LS1, Lenhart G1, Flanders S2,
Huse D1, Dodd SL3, Lomax K4
1 Thomson Medstat, Cambridge, MA, USA; 2 Janssen
Scientific Affairs, Grayslake, IL, USA; 3 Janssen Medical
Affairs, LLC, Silesia, MT, USA; 4 Eisai, Inc, Teaneck, NJ,
USA |
|
PGI7 |
MANAGING CROHN’S DISEASE: USE AND COST OF
INPATIENT, EMERGENCY DEPARTMENT AND OBSERVATION UNIT SERVICES DURING
ONE YEAR
O'Brien J, Pitoniak-Morse C
Caro Research Institute, Concord, MA, USA |
|
PGI8 |
EVALUATION OF OTC PRILOSEC STEP CARE PROGRAMS ON
THE UTILIZATION AND COSTS OF PROTON PUMP INHIBITORS
Sun SX, McMurray J, Jacobsen V, Fuldeore M, Lee K, Zagorski B,
Bertram C
Walgreens Health Initiatives, Deerfield, IL, USA |
|
PGI9 |
MODELING RISK OF GI EVENTS AMONG MEDICAID NSAID
USERS, USING PROPENSITY SCORES
Shaya FT1, Samant N1, Skolasky R2
1 University of Maryland, Baltimore, MD, USA; 2
Johns Hopkins, Baltimore, MD, USA |
|
PGI10 |
IS THE INTRODUCTION OF REFERENCE BASED PRICING
FOR PATENT PROTECTED DRUGS A COST-SAVING OPTION FOR HEALTH CARE?
Kulp W, Greiner W, Schulenburg JM
University of Hanover, Hanover, Germany |
|
PGI11 |
LINKING SYMPTOMS SEVERITY AND DIURNALITY TO
PRODUCTIVITY LOSS - A NEW CONCEPTUAL APPROACH
Nordyke RJ1, Aguilar D1, Lee A1,
Singh A2, Tedeschi MR2, Dubois RW1
1 Cerner Health Insights, Beverly Hills, CA, USA; 2
Wyeth Research, Collegeville, PA, USA |
|
PGI12 |
COMPARISON OF THE MEDICATION POSSESSION RATIO
ALONE AND IN COMBINATION WITH BREAKTHROUGH EVENTS FOR CLASSIFYING
PATIENTS WITH ACID RELATED DISEASES
Brook RA1, Smeeding JE2, Joshua-Gotlib S3,
Warner D3
1 The JeSTARx Group, Newfoundland, NJ, USA; 2
The JeSTARx Group & University of Texas at Austin Center for
Pharmacoeconomic Studies, Dallas, TX, USA; 3 AstraZeneca
Pharmaceuticals LP, Wilmington, DE, USA |
|
PGI13 |
USING ADVANCED SIMULATION MODELING TO EXAMINE THE
IMPACT OF INCREASED RESOURCES ON PATIENT THROUGHPUT IN OUTPATIENT CARE
Lahue BJ1, Lacey MJ1, Dronzek R2
1 Boston Scientific Corporation, Natick, MA, USA; 2
Automation Associates, Inc, Chicago, IL, USA |
|
PGI14 |
DOES A CLINICAL STUDY REFLECT REAL-LIFE AND
REAL-LIFE COSTS
Juhl HH1, Hvenegaard A2, Schmidt VM3,
Habicht A4
1 Danish Institute for Health Services Research,
Copenhagen, Copenhagen, Denmark; 2 Danish Institute for
health Services Research, Copenhagen, Copenhagen, Denmark; 3
Villy Meineche Schmidt, Klampenborg, Copenhagen, Denmark; 4
Signifikans ApS, Vedbaek, Copenhagen, Denmark |
|
PGI15 |
VALIDATION OF EDC VERSIONS OF IBS-QOL, EQ-5D AND
WPAI-IBS QUESTIONNAIRES
Bushnell DM1,
Galani C2, Martin ML1, Ricci JF2,
Reilly M3, Patrick DL4
1 Health Research Associates, Mountlake Terrace, WA, USA;
2 Novartis Pharma AG, Basel, Switzerland; 3
Reilly Associates, New York, NY, USA; 4 University of
Washington, Seattle, WA, USA |
|
PGI16 |
HEALTH RELATED QUALITY OF LIFE CHANGES IN
LAMIVUDINE REFRACTORY CHRONIC HEPATITIS B (CHB) PATIENTS AFTER
ENTECAVIR (ETV) OR LAMIVUDINE (LAM) TREATMENT¡V BMS STUDY 026
Su J1, Chen L1, Iloeje U1,
Cross A1, Hindes R1, Wilber R1,
Johnson J2
1 Bristol-Myers Squibb, Wallingford, CT, USA; 2
University of Alberta, Edmonton, AB, Canada |
|
PGI17 |
TEGASEROD SIGNIFICANTLY IMPROVES QUALITY OF LIFE
IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
Minguez M1, Piqué JM2, Cucala M3,
Bixquert M4, Mascort J5, Sofos S6,
Cobos A7
1 University Clinic Hospital, Valencia, Spain; 2
Clinical Hospital, Barcelona, Spain; 3 Novartis
Farmacéutica S.A, Barcelona, Spain; 4 Arnau de Vilanova
Hospital, Valencia, Spain; 5 ABS La Florida Sud, Barcelona,
Spain; 6 CS Motril Este, Granada, Spain; 7 RDES,
Barcelona, Spain |
METHODS & CONCEPTS
|
PMC1 |
USE OF THRESHOLDS FOR SAFETY REPORTING IN
CLINICAL TRIALS
Frame D, Fahrbach K, Reynolds MW, Ross SD
MetaWorks Inc, Medford, MA, USA |
|
PMC2 |
A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF
GENETIC TESTING TECHNOLOGIES
Ramsey S1, Henrikson N2, Carlson J2,
Veenstra DL2
1 Fred Hutchinson Cancer Research Center, Seattle, WA, USA;
2 University of Washington, Seattle, WA, USA |
|
PMC3 |
INTRODUCTION OF BIAS WHEN USING THE SMEARING
RE-TRANSFORMATION METHOD IN THE PRESENCE OF POSITIVELY SKEWED
ANTI-LOGGED RESIDUALS
Wang MT, Malone DC, Skrepnek GH, Armstrong EP
University of Arizona College of Pharmacy, Tucson, AZ, USA |
|
PMC4 |
THE USE OF A LIFE ANNUITY TO MORE ACCURATELY
CALCULATE MEDICAL COSTS IN A COST-EFFECTIVENESS ANALYSIS
Van Den Bos J
Milliman, Denver, CO, USA |
|
PMC5 |
WITHDRAWN |
|
PMC6 |
ACCURATE AND RAPID PREDICTION OF DRUG PLAN
EXPENDITURE WHILE PLANNING REIMBURSEMENT CHANGES USING POLICY
SIMULATION
Dormuth CR1, Burnett S2, Schneeweiss SM1
1 Harvard University, Boston, MA, USA; 2 Pfia
Corporation, Victoria, BC, Canada |
|
PMC7 |
BRIDGING THE REQUIREMENT-CAPABILITY GAP BETWEEN
DRUG PLAN DECISION MAKERS AND THEIR DATA ANALYSTS IN DRUG POLICY
PLANNING
Burnett S1, Dormuth CR2, Schneeweiss SM2
1 Pfia Corporation, Victoria, BC, Canada; 2
Harvard University, Boston, MA, USA |
|
PMC8 |
WITHDRAWN |
|
PMC9 |
WITHDRAWN |
|
PMC10 |
AN INTERNET-BASED EDUCATIONAL INTERVENTION TO
INCREASE KNOWLEDGE: A RAPID, EFFICIENT, AND EFFECTIVE METHOD
Dubois RW1, Levy W2, Ershler W3,
Kowdley KV4, Lee A1, Christian-Herman J1,
Dean BB1
1 Cerner Health Insights, Beverly Hills, CA, USA; 2
University of Washington, Shoreline, WA, USA; 3 Institute
for Advanced Studies In Aging and Geriatric Medicine, Washington, DC,
USA; 4 University of Washington Medical Center, Seattle,
WA, USA |
|
PMC11 |
WHICH ONE IS LOGICAL? LOGIT OR RARE EVENT LOGIT
(RE-LOGIT)
Baser O1, Long S2
1 Medstat, Inc, Ann Arbor, MI, USA; 2 Medstat,
Inc, Hampden, ME, USA |
|
PMC12 |
WITHDRAWN |
|
PMC13 |
VALUE OF ADDING MEDICAL CLAIMS DATA TO THE
PHARMACY-BASED MODELS PREDICTING FUTURE HEALTH CARE COSTS AND JUMPS IN
COSTS
Parsons O1, Powers CA2, Marks AS1
1 Caremark Inc, Northbrook, IL, USA; 2 Caremark
Inc, Hunt Valley, MD, USA |
|
PMC14 |
EQUIVALENCE OF PAPER AND TOUCH SCREEN VERSIONS OF
THE EQ-5D VISUAL ANALOG SCALE (EQ-VAS)
Ramachandran S1, Taber T2, Craig BM3,
Coons SJ4
1 University of Arizona College of Pharmacy, Tucson, AZ,
USA; 2 Assist Technologies, Scottsdale, AZ, USA; 3
University of Arizona, Tucson, AZ, USA; 4 College of
Pharmacy, Tucson, AZ, USA |
|
PMC15 |
INFLUENCE OF VARIOUS HEALTH STATUS MEASURES ON
TOTAL EXPENDITURES IN THE MEPS DATASET
De Smet BD1, Erickson S2
1 The University of Michigan Health System, Ann Arbor, MI,
USA; 2 University of Michigan, Ann Arbor, MI, USA |
|
PMC16 |
LINKING DISEASE-SPECIFIC QUALITY OF LIFE (QOL)
SCALES
McKenna SP1, Meads DM1, Doward LC1,
Tennant A2
1 Galen Research, Manchester, United Kingdom; 2
University of Leeds, Leeds, United Kingdom |
|
PMC17 |
THE UK EQ-5DINDEX: AN EVALUATION OF
FACE VALIDITY IN HOSPITAL TREATED SUBJECTS
Currie CJ, McEwan P
Cardiff University, Cardiff, United Kingdom |
|
PMC18 |
HEALTH UTILITIES INDEX (HUI) ON-LINE
QUESTIONNAIRE SYSTEM: CRITERION VALIDITY OF MULTI- AND
SINGLE-ATTRIBUTE UTILITY SCORES
Hunter D, Furlong W, Horsman JR
McMaster University, Hamilton, ON, Canada |
|
PMC19 |
IMPROVING THE SCALING PROPERTIES OF THE
PSYCHOLOGICAL GENERAL WELL-BEING SCALE (PGWB)
McKenna SP1, Meads DM1, Doward LC1,
Tennant A2
1 Galen Research, Manchester, United Kingdom; 2
University of Leeds, Leeds, United Kingdom |
|
PMC20 |
RELATIONSHIP BETWEEN PATIENT SATISFACTION AND
PERCEIVED HEALTH STATUS
Xiao H
Florida A&M University, Tallahassee, FL, USA |
|
PMC21 |
WITHDRAWN |
|
PMC22 |
DEVELOPING SYMPTOM-BASED QUESTIONNAIRES FOR
DIAGNOSTIC SCREENING
Nordyke RJ, Halbert RJ
Cerner Health Insights, Beverly Hills, CA, USA |
|
PMC23 |
TRANSLATABILITY ASSESSEMENT: A NEW APPROACH TO
INTERNATIONAL QUESTIONNAIRE DEVELOPMENT
Conway K, Mear I, Rowbotham J, Acquadro C
Mapi Research Institute, Lyon, Rhône, France |
|
PMC24 |
POTENTIAL IMPACT OF HEALTH STATUS ON LIFE
SATISFACTION AND QUALITY OF LIFE: A PILOT STUDY
Chongpison Y, Ramachandran S, Craig BM, Coons SJ
University of Arizona, College of Pharmacy, Tucson, AZ, USA |
|
PMC25 |
SELF-ASSESSED HEALTH STATUS IN THE UNITED STATES:
EQ-5D FINDINGS FROM THE MEDICAL EXPENDITURE PANEL SURVEY
Craig BM1, Ramachandran S2, Coons SJ3
1 University of Arizona, Tucson, AZ, USA; 2
University of Arizona College of Pharmacy, Tucson, AZ, USA; 3
College of Pharmacy, Tucson, AZ, USA |
|
PMC26 |
INTERPRETING THE MAGNITUDE OF SCORE DIFFERENCES
IN THE SF-36 VITALITY SCALE: ASSOCIATION WITH CLINICAL CONDITIONS AND
OUTCOMES
Wallenstein GV1, Bjorner JB1, Martin MC1,
Mody SH2, Piech CT2
1 QualityMetric Incorporated, Lincoln, RI, USA; 2
Ortho Biotech Clinical Affairs LLC, Bridgewater, NJ, USA |
|
PMC27 |
PATIENTS' PERSPECTIVES OF TREATMENT SATISFACTION:
A QUALITATIVE RESEARCH EVALUATION
Colman S, Miller T
Quintiles, San Francisco, CA, USA |
|
PMC28 |
LINGUISTIC VALIDATION
OF THE US SPANISH WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT
QUESTIONNAIRE, GENERAL HEALTH VERSION (WPAI:GH)
Gawlicki MC1, Reilly MC2, Popielnicki A1,
Reilly K2
1 Corporate Translations, Inc, Mansfield Center, CT, USA;
2 Margaret Reilly Associates, Inc, New York, NY, USA |
|
PMC29 |
RECONSIDERING THE PERSPECTIVE IN ECONOMIC
EVALUATION
Seoane-Vazquez EC,
Visaria J, Parekh A
Ohio State University, Columbus, OH, USA |
|
PMC30 |
WITHDRAWN |
|
PMC31 |
AT WHAT COST? A REVIEW OF DRUG ACQUISITION COST
ISSUES IN MODELLED ECONOMIC EVALUATIONS.
Wonder M1, Backhouse M2, Gnanasakthy A2
1 Novartis Pharmaceuticals, Sydney, Australia; 2
Novartis Pharmaceuticals, Basel, Switzerland |
|
PMC32 |
USING MARKOV MATRICES TO INTEGRATE RISK/BENEFIT
CONSIDERATIONS OF HEALTH CARE INTERVENTIONS EVALUATED USING
HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS
Casado A,
Herdman MJ
3D Health Research, Barcelona, Barcelona, Spain |
|
PMC33 |
BRIDGING BEYOND REGRESSION--ARTIFICIAL NEURAL
NETWORK IN MAPPING FROM SF-36 TO HEALTH UTILITY
Yu AP1, Yu YF2, Nichol MB3
1 University of Southern California, Los Angeles, CA, USA;
2 HealthCore, Inc, Wilmington, DE, USA; 3
University of Southern California, School of Pharmacy, Los Angeles,
CA, USA |
MENTAL
HEALTH-ALCOHOLISM / DRUG ABUSE
|
PMH1 |
HEALTH CARE AND WORKLOSS COSTS OF OPIOID ABUSE
AMONG AN EMPLOYED POPULATION IN THE US
White AG1, Birnbaum H1, Mareva MN1,
Daher M1, Katz N2, Vallow S3, Schein
J3, Doshi D4, Sikirica V3
1 Analysis Group, Inc, Boston, MA, USA; 2
Inflexxion, Inc, Newton, MA, USA; 3 Janssen Medical
Affairs, LLC, Titusville, NJ, USA; 4 Janssen Medical
Affairs, LLC, San Diego, CA, USA |
|
PMH3 |
QUALITY-ADJUSTED LIFE YEARS GAINED WITH
BUPRENORPHINE TREATMENT FOR OPIATE ADDICTION
Campbell HM1, Raisch DW1, Ling W2
1 VA Cooperative Studies Program, Albuquerque, NM, USA;
2 David Geffen School of Medicine at UCLA, Los Angeles, CA,
USA |
MENTAL
HEALTH-ANXIETY
|
PMH4 |
COST-EFFECTIVENESS OF ALPRAZOLAM IN ANXIETY
DISORDERS
García-Contreras F, Castro-Ríos A, Nevarez-Sida A,
Constantino-Casas P, Contreras-Hernández I, Mould J, Garduño-Espinosa
J
Mexican Institute of Social Security, Mexico City, Mexico |
|
PMH5 |
ECONOMIC BURDEN OF GENERALIZED ANXIETY DISORDER
(GAD) AND OTHER ANXIETY DISORDERS
Chang S1, Mark TL1, Brandenburg N2
1 Medstat, Washington, DC, USA; 2 Pfizer, Inc,
New York, NY, USA |
|
PMH6 |
DETERMINANTS OF PERMANENT NUSRING HOME ADMISSIONS
AMONG ELDERLY IN THE UNITED STATES
Cai QC, Lin SJ
University of Illinois, Chicago, IL, USA |
|
PMH7 |
THE EFFECT OF VENLAFAXINE, PAROXETINE, AND
PLACEBO ON HEALTH-RELATED WORK PRODUCTIVITY IN PANIC DISORDER PATIENTS
Khandker R, Zhang HF
Wyeth Research, Collegeville, PA, USA |
MENTAL HEALTH-Attention
Deficit Disorder
MENTAL HEALTH-Bi-Polar
Disorder
|
PMH9 |
ESTIMATING THE BUDGET IMPACT OF QUETIAPINE FOR
THE TREATMENT OF ACUTE MANIA AMONG HOSPITALIZED PATIENTS
Caro JJ1, Lee KM1,
Huybrechts K1, Rajagopalan K2
1 Caro Research, Concord, MA, USA; 2 AstraZeneca
Pharmaceuticals LP, Wilmington, DE, USA |
|
PMH10 |
MENTAL HEALTH COST COMPARISON AMONG PATIENTS WITH
BIPOLAR DISORDER TREATED WITH RISPERIDONE VERSUS OLANZAPINE OR
QUETIAPINE IN A MANAGED CARE SETTING: A PROPENSITY-MATCHED COHORT
STUDY
Gutierrez B1,
Meletiche D2, Rupnow MF2, Blount A1,
Boccuzzi SJ1
1 Aetna Health Information Solutions, Blue Bell, PA, USA;
2 Janssen Medical Affairs, LLC, Titusville, NJ, USA |
|
PMH11 |
ANTIPSYCHOTIC USE AND HOSPITALIZATION IN BIPOLAR
OR MANIC PATIENTS
Gianfrancesco F1, Rajagopalan K2
1 HECON Associates, Montgomery Village, MD, USA; 2
AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA |
|
PMH12 |
PREVALANCE AND COST OF BIPOLAR DISORDER AND
TREATMENT WITHIN A MANAGED CARE ORGANIZATION
Lew KH1, Chang EY1, Knoth RL1,
Fontes CL1, Rajagopalan K2
1 Prescription Solutions, Costa Mesa, CA, USA; 2
AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA |
|
PMH13 |
THE CLINICAL AND ECONOMIC OUTCOMES OF
SECOND-GENERATION ANTIDEPRESSANT USE FOR BIPOLAR DISORDER
Fu AZ, Liu GG, Christensen DB, Hansen RA
University of North Carolina, Chapel Hill, NC, USA |
|
PMH14 |
A CASE-CONTROL STUDY ON SECOND-GENERATION
ANTIDEPRESSANT USE IN PATIENTS WITH BIPOLAR DISORDER
Fu AZ, Christensen DB
University of North Carolina, Chapel Hill, NC, USA |
|
PMH15 |
STUDY GAPS IN ECONOMIC EVALUATIONS OF
PHARMACOTHERAPY IN BIPOLAR DISORDER
Hassan MK, Kavookjian J, Madhavan SM
West Virginia University, Morgantown, WV, USA |
|
PMH16 |
MEASURING THE EFFECT OF A POLICY CHANGE IN
MONTHLY PRESCRIPTION LIMIT ON HEALTH CARE UTILIZATION AND EXPENDITURE:
A CONTROLLED COMPARISON OF OLS AND PANEL ESTIMATION
Perkins PI, Johnson ED, Dickson WM
University of South Carolina, Columbia, SC, USA |
|
PMH17 |
COMPARING PROPENSITY SCORE AND
DIFFERENCE-IN-DIFFERENCE METHODS: SECOND-GENERATION ANTIDEPRESSANT USE
FOR BIPOLAR DISORDER
Fu AZ1, Dow WH2, Liu GG1
1 University of North Carolina, Chapel Hill, NC, USA;
2 University of California, Berkeley, CA, USA |
|
PMH18 |
AN EXPLORATORY STUDY TO DEVELOP A MODEL OF
QUALITY OF LIFE FOR BIPOLAR DISORDER
Doward LC1, Tai SJ2, Taylor JL2
1 Galen Research, Manchester, United Kingdom; 2
University of Manchester, Manchester, United Kingdom |
|
PMH66 |
INCREMENTAL HEALTH BENEFITS COST OF
BIPOLAR DISORDER AMONG INSURED EMPLOYEES
Kleinman NL1,
Brook RA2, Gardner H1, Rajagopalan K"3,
Smeeding JE4
1 Human Capital Management Services, Cheyenne, WY, USA;
2 The JeSTARx Group, Newfoundland, NJ, USA; 3
AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA; 4
The JeSTARx Group & University of Texas at Austin Center for
Pharmacoeconomic Studies, Dallas, TX, USA |
|
PMH19 |
TREATMENT ADHERENCE WITH ANTIPSYCHOTICS AMONG
BIPOLAR AND MANIC PATIENTS
Gianfrancesco F1, Rajagopalan K2
1 HECON Associates, Montgomery Village, MD, USA; 2
AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA |
MENTAL HEALTH-Depression
|
PMH20 |
PATTERNS OF DEMENTIA/ALZHEIMER MANAGEMENT AMONG
ELDERLY PATIENTS IN US AMBULATORY CARE
Maneno M, Wutoh A, Jackson P, Lombardo F, Scott K, Xue Z, Lee
E
Howard University, Washington DC, DC, USA |
|
PMH21 |
COSTS OF DEMENTIA AMONG COMMUNITY DWELLING
PATIENTS
Bharmal M, Thomas III J
Purdue University, West Lafayette, IN, USA |
|
PMH22 |
PREDICTORS OF HEALTH RELATED QUALITY OF LIFE
AMONG DEMENTIA CAREGIVERS: A LONGITUDINAL EXAMINATION
Madan A1, Clay O1, Kilgore M1,
Roth D1, Mittelman M2
1 University of Alabama at Birmingham, Birmingham, AL, USA;
2 New York University School of Medicine, New York, NY, USA |
|
PMH23 |
ASSESSING VENLAFAXINE, SERTRALINE, OR PLACEBO
TREATMENT ON IMPROVEMENT IN GENERAL LIFE FUNCTIONING AMONG DEPRESSED
PATIENTS
Zhang HF, Khandker R
Wyeth Research, Collegeville, PA, USA |
|
PMH24 |
IMPROVEMENT OF FATIGUE IN PATIENTS WITH MAJOR
DEPRESSIVE DISORDER TREATED WITH VENLAFAXINE, SERTRALINE, OR PLACEBO
Zhang HF, Khandker R
Wyeth Research, Collegeville, PA, USA |
|
PMH25 |
COST AND UTILIZATION DIFFERENCES AMONG CARDIAC
PATIENTS TREATED FOR DEPRESSION WITH ZOLOFT VERSUS NO PHARMACEUTICAL
TREATMENT
Bron MS1, Mark TL2, Orsini LS3
1 Pfizer, New York, NY, USA; 2 Medstat,
Washington, DC, USA; 3 MedStat, Inc, Cambridge, MA, USA |
|
PMH26 |
COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN
THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN TURKEY
Hemels ME1, Karamustafalýoglu O2, Ozmen
E3, Dilsad S4, Mene S3
1 H. Lundbeck A/S, Paris, Ile de France, France; 2
Etfal Hospital, Istanbul, Sisli, Turkey; 3 Lundbeck Ìlaç
Ticaret Limited, Istanbul, Ìlaç, Turkey; 4 Marmara
University, Istanbul, Istanbul, Turkey |
|
PMH27 |
COST-EFFECTIVENESS OF ESCITALOPRAM VS. VENLAFAXIN
XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN GERMANY
Kulp W1, Greiner W2, Schulenburg JM3
1 University of Hannover, Hannover, D, Germany; 2
University of Hannover, Hannover, D-, Germany; 3 University
of Hannover, Hannover, Germany |
|
PMH28 |
A COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM AND
SERTRALINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
Armstrong EP1, Skrepnek GH1, Malone DC1,
Erder H2
1 University of Arizona College of Pharmacy, Tucson, AZ,
USA; 2 Forest Research Institute, Jersey City, NJ, USA |
|
PMH29 |
THE EFFECT OF RAISING THREE TIER COPAYMENTS ON
SSRI COMPLIANCE RATES
Bron MS1, Mark TL2
1 Pfizer, New York, NY, USA; 2 Medstat,
Washington, DC, USA |
|
PMH30 |
OUTCOME ANALYSIS OF A MULTI-LEVEL INTERVENTION
PROGRAM TO IMPROVE ANTIDEPRESSANT MEDICATION ADHERENCE
Alison L1, Wong SL2
1 Healthfirst, New York, NY, USA; 2 Pfizer Inc,
Syosset, NY, USA |
|
PMH31 |
THE RELATIVE PERFORMANCE OF NEWER ANTIDEPRESSANTS
IN A MEDICAID POPULATION
McCombs JS1, Park J1, Bron MS2
1 University of Southern California, Los Angeles, CA, USA;
2 Pfizer, New York, NY, USA |
|
PMH32 |
APPROPRIATENESS AND VARIATION IN DRUG UTILIZATION
ACROSS PATIENTS WITH DEPRESSION
Long S1, Robinson R2, Chang S3,
Able S2, Baser O4, Swindle R5
1 Medstat, Inc, Hampden, ME, USA; 2 Eli Lilly
and Company, Indianapolis, IN, USA; 3 Medstat, Inc,
Washington, DC, USA; 4 Medstat, Inc, Ann Arbor, MI, USA;
5 Lilly Research Laboratories, Indianapolis, IN, USA |
|
PMH33 |
DRUG UTILIZATION AND MARKET-SHARE COMPETITION
AMONG ANTIDEPRESSANT MEDICATIONS IN US MEDICAID PROGRAMS
Guo JJ, Chen Y, Jing Y, Patel NC
University of Cincinnati, Cincinnati, OH, USA |
|
PMH34 |
IMPACT OF RELABELING ON NEFAZODONE PRESCRIBING: A
RISK MINIMIZATION EVALUATION
Morrato EH, Valuck RJ
University of Colorado, Denver, CO, USA |
|
PMH35 |
THE MAIN AND INTERACTION EFFECTS OF PATIENT AND
PHYSICIAN CHARACTERISTICS IN INFLUENCING THE PRESCRIBING OF
ANTIDEPRESSANTS
Tan H1, Lin SJ2, Lambert BL3,
Sclove SL3
1 HealthCore, WILMINGTON, DE, USA; 2 University
of Illinois, Chicago, IL, USA; 3 University of Illinois at
Chicago, Chicago, IL, USA |
|
PMH36 |
RASCH MODEL COMPARISON OF BECK DEPRESSION INDEX
AND MOOD AND ANXIETY SYMPTOMS QUESTIONNAIRE IN MEASUREMENT OF
DEPRESSION
Wang ZX, Conrad KJ, Hankin BL, Huang ZG
University of Illinois at Chicago, Chicago, IL, USA |
|
PMH37 |
A SYSTEMATIC REVIEW OF SUICIDALITY MEASURES IN
STUDIES USING SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN
CHILDREN AND ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
Pfalzgraf AR, Kavookjian J, Scott V
West Virginia University, Morgantown, WV, USA |
|
PMH38 |
COMPARING EXHAUSTIVE CHAID CLASSIFICATION TREE
AND FORWARD STEPWISE LOGISTIC REGRESSION (LR) IN EXPLAINING THE
PRESCRIBING OF ANTIDEPRESSANTS
Tan H1, Lin SJ2, Lambert BL3,
Sclove SL2
1 HealthCore, WILMINGTON, DE, USA; 2 University
of Illinois, Chicago, IL, USA; 3 University of Illinois at
Chicago, Chicago, IL, USA |
|
PMH39 |
THE USEFULNESS OF THE EQ-5D IN DIFFERENTIATING
AMONG PERSONS WITH MAJOR DEPRESSIVE EPISODE AND ANXIETY
Supina AL1, Johnson J2, Maxwell CJ1,
Patten SB1, Williams J1
1 University of Calgary, Calgary, AB, Canada; 2
University of Alberta, Edmonton, AB, Canada |
|
PMH40 |
QUALITY-ADJUSTED REMISSION FREE DAYS: AN EXTENDED
Q-TWIST APPLICATION IN MAJOR DEPRESSION DISORDER
Zhang HF, Khandker R
Wyeth Research, Collegeville, PA, USA |
|
PMH41 |
QUALITY OF LIFE, EMOTIONAL AND PHYSICAL SYMPTOMS
IN DEPRESSION : A LITERATURE REVIEW OF SYMPTOMATOLOGY AND PATIENT
REPORTED OUTCOME (PRO) INSTRUMENTS
Garcia-Cebrian A1, Staniek V2,
Hugonot-Diener L3, Arnould B4, Monz B5
1 Eli Lilly and Company Limited, Surrey, United Kingdom;
2 Mapi Research Trust, Lyon, France; 3 MedForma,
Paris, France; 4 Mapi Values, Lyon, France; 5
Boehringer Ingelheim GmbH, Ingelheim, Germany |
MENTAL HEALTH-Psychosis
|
PMH42 |
HOSPITALIZATION AND EMERGENCY ROOM VISITS BEFORE
AND AFTER TREATMENT WITH ATYPICAL ANTIPSYCHOTICS
Rajagopalan K1, Lage MJ2
1 AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA;
2 HealthMetrics Outcomes Research, Groton, CT, USA |
|
PMH43 |
IMPACT OF A PSYCHOEDUCATION PROGRAM ON HEALTH
STATUS OF SEVERE AND PERSISTENTLY MENTALLY ILL
Bellnier T1, Pearce J2
1 SUNY University at Buffalo, Buffalo, NY, USA; 2
GPI, Inc, Rochester, NY, USA |
|
PMH44 |
PERCEPTION OF SIDE EFFECTS, MEDICATION ADHERENCE
AND QUALITY OF LIFE IN PSYCHIATRIC PATIENTS
Lapshin O, Joshi A, Finkelstein J
University of Maryland, Baltimore, MD, USA |
MENTAL HEALTH-Schizophrenia
|
PMH45 |
HISTORY OF SUBSTANCE ABUSE ASSOCIATED WITH POOR
PROGNOSIS IN THE TREATMENT OF SCHIZOPHRENIA: RESULTS FROM A CLINICAL
TRIAL DATABASE
Kinon B, Liu-Seifert H,
Adams DH
Eli Lilly and Company, Indianapolis, IN, USA |
|
PMH46 |
RELIABILITY AND VALIDITY OF THE READINESS FOR
DISCHARGE QUESTIONNAIRE IN SCHIZOPHRENIA
Ruetsch C1,
Rupnow MF2, Revicki DA1, Kosik-Gonzalez
C2, Greenspan A2, Gharabawi G2
1 Medtap International, Inc, Bethesda, MD, USA; 2
Janssen Pharmaceutica Inc., A General Partner of Janssen Pharmceutica
Products, L.P, Titusville, NJ, USA |
|
PMH47 |
USE AND COST OF POLYPHARMACY IN SCHIZOPHRENIA:
DATA FROM A RANDOMIZED, DOUBLE-BLIND STUDY OF RISPERIDONE AND
QUETIAPINE
Rupnow MF1, Greenspan A1, Kosik-Gonzalez
C1, Zhu Y2, Gharabawi G1, Stahl SM3
1 Janssen Pharmaceutica Inc., A General Partner of Janssen
Pharmaceutica Products, LP, Titusville, NJ, USA; 2 Janssen
Ortho McNeil Pharmaceutica Services, Scientific Affairs Center of
Excellence, Titusville, NJ, USA; 3 Neuroscience Education
Institution, Carlsbad, CA, USA |
|
PMH48 |
SYSTEMATIC REVIEW ON RELAPSE AND ANTIPSYCHOTIC
NON-ADHERENCE IN SCHIZOPHRENIA
Shi L1, Taylor M2, Remond S2,
Chaplin S2, Duffy S2, West P2
1 Eli Lilly and Company, Indianapolis, IN, USA; 2
York Health Economics Consortium, Heslington, York, United Kingdom |
|
PMH49 |
ESTIMATING ANNUAL US PREVALENCE OF SCHIZOPHRENIA
IN 2002
Wu EQ, Birnbaum H, Aggarwal J, Moulis M
Analysis Group, Inc, Boston, MA, USA |
|
PMH50 |
A PSYCHIATRIC HOSPITAL REVENUE AND PROFITABILITY
MODEL FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN JAPAN
Makino K1, Matsushita T2,
Davey P1, Narita M2, Mori S2,
Kimuro Y2
1 Medical Technology Assessment Group Pty Ltd, Sydney, NSW,
Australia; 2 Eli Lilly Japan K.K, Kobe, Hyogo Prefecture,
Japan |
|
PMH51 |
COST-EFFECTIVENESS EVALUATION OF LONG-ACTING
RISPERIDONE
Locklear J1, Edwards N2, Rupnow MF1,
Diamond R3
1 Janssen Medical Affairs, LLC, Titusville, NJ, USA; 2
Health Services Consulting, Inc, Boxborough, MA, USA; 3
Department of Mental Health of Dane County, Madison, WI, USA |
|
PMH52 |
THE COST OF RELAPSE IN SCHIZOPHRENIA IN THE
UNITED STATES
Ascher-Svanum H1, Zhu B1, Faries DE1,
Jiang Q1, Salkever D2, Slade E3
1 Eli Lilly and Company, Indianapolis, IN, USA; 2
Johns Hopkins University, Baltimore, MD, USA; 3 University
of Maryland, Baltimore, MD, USA |
|
PMH2 |
COSTS OF TREATING CRISIS-PRONE
SCHIZOPHRENIA PATIENTS
Zhu B1, Ascher-Svanum H1, Faries DE1, Jiang Q1, Salkever D2, Slade
E3, 1Eli Lilly and
Company, Indianapolis, IN, USA; 2Johns Hopkins Bloomberg School of
Public Health, altimore, MD, USA; 3University of Maryland, Baltimore, MD, USA |
|
PMH53 |
DIRECT HEALTH CARE COSTS OF SCHIZOPHRENIA IN THE
UNITED STATES: 2002
Wu EQ1, Birnbaum H1, Kessler R2,
Beaulieu N1, Daher M1, Aggarwal J1,
Ascher-Svanum H3, Shi L3
1 Analysis Group, Inc, Boston, MA, USA; 2
Harvard Medical School, Boston, MA, USA; 3 Eli Lilly and
Company, Indianapolis, IN, USA |
|
PMH54 |
DIFFERENTIAL RISKS AND ASSOCIATED COSTS OF
HOSPITALIZATION DURING ANTIPSYCHOTIC TREATMENT IN MEDICAID PATIENTS
WITH SCHIZOPHRENIA
Gianfrancesco F1, Pesa J2
1 HECON Associates, Montgomery Village, MD, USA; 2
AstraZeneca LP, Wilmington, DE, USA |
|
PMH55 |
CLASSIFYING ANTIPSYCHOTIC ADHERENCE USING LATENT
CLASSES ANALYSIS: CHARACTERISTICS OF NON-ADHERENT CASEMIX IN THE
CALIFORNIA MEDICAID (MEDICAL) PROGRAM
Ahn J1, McCombs JS1, Jung C1,
Croudace TJ2, McDonnell D3, Ascher-Svanum H3,
Edgell E3, Shi L3
1 University of Southern California, Los Angeles, CA, USA;
2 University of Cambridge, Cambridge, United Kingdom;
3 Eli Lilly and Company, Indianapolis, IN, USA |
|
PMH56 |
STARTING DOSE AND PERSISTENCE FOR ZIPRASIDONE
USERS IN MEDICAID
Mullins CD1, Shaya FT2, Zito J2,
Gardner J2, McNally D2, Meng F2,
Harrison D3
1 Pharmaceutical Health Services Research, Baltimore, MD,
USA; 2 University of Maryland, Baltimore, MD, USA; 3
Pfizer Inc, New York, NY, USA |
|
PMH57 |
ELECTRONIC MONITORING OF ANTIPSYCHOTIC ADHERENCE
OF OUTPATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER AND
ASSOCIATION WITH SYMPTOMS, QUALITY OF LIFE AND COGNITION
Byerly M1,
Thompson A2, Carmody T1, Erwin T1,
Bugno R1, Rush J1
1 University of Texas Southwestern, Dallas, TX, USA; 2
Janssen Medical Affairs, LLC, Leawood, KS, USA |
|
PMH58 |
THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE
REGISTRY – E-STAR: BASELINE RESULTS FOR GERMANY
Naber D1, Mehnert A2, Rosillon D3,
Farmer D4, Schreiner A2,
Jacobs A5
1 University Hospital Hamburg-Eppendorf, Hamburg, Germany;
2 Janssen-Cilag GmbH, Neuss, Germany; 3 SGS
Biopharma, Wavre, Belgium; 4 Interactive Educational
Systems, Ltd, Hampton Court, Surrey, United Kingdom; 5
Janssen Pharmaceutica, Beerse, Belgium |
|
PMH59 |
THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE
REGISTRY — E-STAR: BASELINE RESULTS FOR GERMANY, SPAIN AND AUSTRALIA
Rossillon D1, Caleo S2, Farmer D3,
Ingham M4,
Jacobs A2
1 SGS Biopharma, Wavre, Belgium; 2 Janssen
Pharmaceutica, Beerse, Belgium; 3 Interactive Educational
Systems, Ltd, Hampton Court, Surrey, United Kingdom; 4
Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA |
|
PMH60 |
THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE
REGISTRY – E-STAR : DATA QUALITY ASSURANCE GATE KEEPING METHODS
Farmer D1, Ingham M2,
Jacobs A3
1 Interactive Educational Systems, Ltd, Hampton Court,
Surrey, United Kingdom; 2 Johnson & Johnson Pharmaceutical
Services, Raritan, NJ, USA; 3 Janssen Pharmaceutica,
Beerse, Belgium |
|
PMH61 |
COMPARISON OF OUTCOMES REPORTED BY INDIVIDUALS
WITH SCHIZOPHRENIA RESIDING IN THE COMMUNITY AND OBJECTIVE OUTCOMES
REPORTED BY CAREGIVERS
Barr J, Schumacher G, Ohman S, Mason E
Northeastern University, Boston, MA, USA |
|
PMH62 |
VALUATION OF SCHIZOPHRENIA-RELATED HEALTH STATES
BY THE GENERAL POPULATION USING THE AQOL, TIME TRADE-OFF AND VISUAL
ANALOGUE SCALES
Adams J1, Le Reun C1, Crowley S2,
Nand V2,
Eggleston A2, Schrover R2
1 M-Tag Pty Ltd, Chatswood, NSW, Australia; 2
Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia |
|
PMH63 |
GREATER DEPRESSIVE SYMPTOMS ARE ASSOCIATED WITH
WORSE FUNCTIONAL OUTCOMES IN PATIENTS DIAGNOSED WITH SCHIZOPHRENIA OR
SCHIZOAFFECTIVE DISORDER
Phillips GA, Ascher-Svanum H, Chen L, Kinon B
Eli Lilly and Company, Indianapolis, IN, USA |
|
PMH64 |
USE OF THE CAREGIVER STRAIN QUESTIONNAIRE IN AN
INTERNATIONAL STUDY
Mear I1, D'Uva F1, Brannan AM2,
Pesa J3, Olexy C3
1 Mapi Research Institute, Lyon, Rhône, France; 2
Vanderbilt University, Nashville, TN, USA; 3 AstraZeneca
LP, Wilmington, DE, USA |
|
PMH65 |
IMPACT OF ATYPICAL AGENTS ON OUTCOMES OF CARE IN
SCHIZOPHRENIC PATIENTS
Joyce AT1, Harrison D2, Ollendorf DA1
1 PharMetrics, Watertown, MA, USA; 2 Pfizer Inc,
New York, NY, USA |
MUSCULAR-SKELETAL
DISORDERS
|
PMS1 |
INCREMENTAL DIRECT COST OF BACK PAIN IN THE
UNITED STATES IN 2001
Balu S, Thomas J
Purdue University, West Lafayette, IN, USA |
|
PMS2 |
EVALUATION OF AN AUTOMATED SYSTEM FOR PRIOR
AUTHORIZATION - A COX-2 INHIBITOR EXAMPLE
Carroll NV1, Smith JC2, Berringer RA3,
Oestreich GL4
1 Virginia Commonwealth University School of Pharm,
Richmond, VA, USA; 2 Affiliated Computer Services,
Richmond, VA, USA; 3 University of Pittsburgh, Pittsburgh,
PA, USA; 4 Missouri Division of Medical Services, Jefferson
City, MO, USA |
OBESITY
|
POB1 |
COMPARISON OF WEIGHT REDUCTION AND SATISFACTION
OF ORLISTAT AND SIBUTRAMINE
Mekaroonreung S, Auamnoy T, Thaweechotepatara P
Chulalongkorn University, Bangkok, Thailand |
|
POB2 |
RECENT TRENDS AND A FUTURE FORECAST OF POPULATION
BODY MASS INDEX LEVELS IN THE UNITED KINGDOM
Woehl A1, Currie CJ2
1 Kiel University, Kiel, Germany; 2 Cardiff
University, Cardiff, United Kingdom |
|
POB3 |
PREVALENCE TRENDS OF OVERWEIGHT AND OBESITY AND
TREATMENT PATTERNS FOR WEIGHT CONTROL IN THE US POPULATION
Vo L, Valiyeva E, Shin HC, Suh DC, Barone JA
Rutgers University, Piscataway, NJ, USA |
|
POB4 |
RELIABLE MEASUREMENT OF OBESITY: RISK OF VASCULAR
DISEASE COMPLICATIONS AS A FUNCTION OF BODY MASS INDEX AND WAIST-TO-
HIP RATIO
Woehl A1, Currie CJ2, McEwan P2,
Peters JR3
1 Kiel University, Kiel, Germany; 2 Cardiff
University, Cardiff, United Kingdom; 3 University Hospital
of Wales, Cardiff, United Kingdom |
|
POB5 |
COST EFFECTIVENESS OF SIBUTRAMINE IN THE
LONG-TERM OUTCOMES OF SIBUTRAMINE EFFECTIVENESS ON WEIGHT STUDY
Malone D1, Raebel M2, Porter JA3,
Lanty F4, Conner DA2, Merenich JA2,
Vogel EA4
1 University of Arizona, Tucson, AZ, USA; 2
Kaiser Permanente, Denver, CO, USA; 3 Sanofi-Aventis
Pharmaceuticals, Bridgewater, NJ, USA; 4 Kaiser Permanente,
Aurora, CO, USA |
|
POB6 |
COSTS OF OBESITY IN THE UNITED STATES AND EUROPE:
A REVIEW OF THE LITERATURE
Budhiarso I, Derleth A, Martin ML
Health Research Associates, Mountlake Terrace, WA, USA |
|
POB7 |
LIFETIME COSTS ASSOCIATED WITH OBESITY: A
COMPUTER SIMULATION MODEL
Tucker DM1, Minshall ME2, Palmer AJ1,
Valentine WJ1
1 CORE - Center for Outcomes Research, Binningen, Basel,
Switzerland; 2 CORE - USA, Fishers, IN, USA |
OSTEOPOROSIS
|
POS1 |
USING A BUDGET IMPACT MODEL TO PREDICT FIRST-YEAR
USE OF A NEW OSTEOPOROSIS THERAPY
Sasser A1, Rousculp MD2,
Birnbaum H1, Moyneur E1, Wu EQ1,
Marcus R2
1 Analysis Group, Inc, Boston, MA, USA; 2 Eli
Lilly and Company, Indianapolis, IN, USA |
|
POS2 |
ALENDRONATE AND HORMONE REPLACEMENT THERAPY (HRT)
IN THE PREVENTION OF OSTEOPOROTIC FRACTURE IN THE DEPARTMENT OF
DEFENSE (DOD): AN ANALYSIS USING NET-BENEFIT REGRESSION
Tiller KW1, Rascati KL2, Wilson JP2
1 Department of Defense Pharmacoeconomic Center, Fort Sam
Houston, TX, USA; 2 University of Texas, Austin, TX, USA |
|
POS3 |
COST-EFFECTIVENESS ANALYSIS OF BIPHOSPHONATES AND
RALOXIFENE FOR TREATMENT OF OSTEOPOROSIS AND PREVENTION OF FRACTURES
Lau TC1,
Lim BP2, Li SC3
1 Tan Tock Seng Hospital, Singapore, Singapore, Singapore;
2 National Health Care Group, Singapore, Singapore,
Singapore; 3 National University Singapore, Singapore,
Singapore, Singapore |
|
POS4 |
FACTORS AFFECTING THE BONE DENSITY TEST
PRESCRIBING FOR OSTEOPOROSIS IN MALE AMBULATORY PATIENTS
Rahman A
Shenandoah University, Winchester, VA, USA |
|
POS5 |
POST-OSTEOPOROTIC FRACTURE DRUG TREATMENT FOR
OSTEOPOROSIS IN NURSING HOME ELDERLY
Ye X, Eberly LE, Harms SL, Garrard JM
University of Minnesota, Minneapolis, MN, USA |
|
POS6 |
IMPACT OF AN OSTEOPOROSIS INTERVENTION PROGRAM OF
PATIENTS WITH A FRACTURE HISTORY
Park J1, Ara SB2
1 Health Net Pharmaceutical Services, San Bernardino, CA,
USA; 2 Health Net Pharmaceutical Services, Woodland Hills,
CA, USA |
|
POS7 |
VALIDATION STUDY OF THE OSTEOPOROSIS PATIENT
SATISFACTION QUESTIONNAIRE (OPSAT-Q)
Flood E1, Beusterien K1, Baran R2,
Shikiar R3, Cella D4
1 MEDTAP International, Bethesda, MD, USA; 2
Roche Laboratories Inc, Nutley, NJ, USA; 3 MEDTAP
International, Seattle, WA, USA; 4 Evanston Northwestern
Healthcare, Evanston, IL, USA |
PAIN
|
PPN1 |
REDUCING MORTALITY IN PATIENTS WITH SUBSTANCE
ABUSE AND CHRONIC NON-MALIGNANT PAIN THROUGH A MULTIDISCIPLINARY
OPIOID RENEWAL CLINIC
Sampson JM,
Marsh B
VA Medical Center, Gainesville, FL, USA |
|
PPN2 |
EVALUATION OF THE DIRECT COSTS OF PURE
NEUROPATHIC PAIN MANAGEMENT IN FRANCE BEFORE A FIRST CONSULTATION IN A
PAIN MANAGEMENT CENTER
Duru G1, Garassus P2, Lantéri-Minet M3,
Lamarsalle L4, Von Raison F5, Solesse-de
Gendre A5
1 Université C. Bernard Lyon I, Villeurbanne, France;
2 Clinique du Tonkin, Villeurbanne, France; 3 Hôpital
Pasteur, NICE, France; 4 GYD Institut - IMS Health, Lyon,
France; 5 Pfizer, Paris cedex 14, France |
|
PPN3 |
SUMMARY OF HOSPITAL LOGISTICS ASSOCIATED WITH
INTRAVENOUS PATIENT-CONTROLLED ANALGESIA (IV PCA) FOR ACUTE
POSTOPERATIVE PAIN MANAGEMENT
Zhang M1, Anastassopoulos K2, Hutchison
R3, Olson WH1, Goss TF2, Hewitt D1,
Gargiulo K1, Siccardi M1, Mordin M2
1 Ortho McNeil Pharmaceutical, Inc, Raritan, NJ, USA;
2 Covance Health Economics and Outcomes Services Inc,
Gaithersburg, MD, USA; 3 Presbyterian Hospital, Dallas, TX,
USA |
|
PPN4 |
PARENTS' PERCEPTION OF THE SAFETY OF PEDIATRIC
NON-PRESCRIPTION DRUGS - ACETAMINOPHEN AS AN EXAMPLE
Rabinovich M1, Shani S2, Ben-Zvi Z2
1 Maccabi Healthcare Services, Tel-Aviv, Israel; 2
Ben-Gurion University of the Negev, Beer-Sheva, Israel |
|
PPN5 |
TYPES OF PROBLEMS ASSOCIATED WITH INTRAVENOUS
PATIENT-CONTROLLED ANALGESIA (IV PCA) INFUSION PUMPS: AN ANALYSIS OF
THE MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE
Hankin C1, Zhang M2
1 BioMedEcon, LLC, San Jose, CA, USA; 2 Ortho
McNeil Pharmaceutical, Inc, Raritan, NJ, USA |
|
PPN6 |
RETROSPECTIVE ANALYSIS OF DRUG UTILIZATION
PATTERNS IN CANCER AND NON-CANCER PATIENTS TREATED WITH TRANSDERMAL
BUPRENORPHINE AND TRANSDERMAL FENTANYL
Poulsen Nautrup B1, Nuijten M2
1 Gruenenthal GmbH, Aachen, Germany, Germany; 2
Medtap International Inc, Jisp, Netherlands, Netherlands |
|
PPN7 |
CONFIRMATORY FACTOR ANALYSIS OF THE BECK
DEPRESSION INVENTORY
Panjabi SS1, Shepherd M1, Panjabi R2
1 University of Texas at Austin, Austin, TX, USA; 2
Advanced Pain Management and Rehab Medical Group Inc, Castro Valley,
CA, USA |
|
PPN8 |
DEVELOPMENT OF DIFFERENT LANGUAGE VERSIONS OF A
US BACK PAIN QUESTIONNAIRE
Conway K1, Chevallet L1, Barber B2,
Gavart S2, Nevitt MC3
1 Mapi Research Institute, Lyon, Rhône, France; 2
Eli Lilly and Company, Indianapolis, IN, USA; 3 UCSF
Coordinating Center, San Francisco, CA, USA |
|
PPN9 |
SEVERE PAIN IN PERSONS WHO RECEIVED HOSPICE CARE
IN THE UNITED STATES (US)
Strassels SA1, Sullivan SD1, Blough DK1,
Hazlet TK1, Maxwell T2, Reifsnyder J2,
Veenstra DL1
1 University of Washington, Seattle, WA, USA; 2
excelleRx, Inc, Philadelphia, PA, USA |
|
PPN10 |
PATIENT SATISFACTION WITH PAIN MANAGEMENT 28 DAYS
AFTER TOTAL KNEE ARTHROPLASTY
Strassels SA1, Grossman P2, Blough DK1,
Sullivan SD1, Colucci S2, Richards P2,
Strauss ME2
1 University of Washington, Seattle, WA, USA; 2
Purdue Pharma, LP, Stamford, CT, USA |
URINARY/KIDNEY
|
PUK1 |
SELECTED OUTCOMES IN PATIENTS WITH OVERACTIVE
BLADDER COMPARED TO NON-OVERACTIVE BLADDER CONTROLS
Daniel G1, Kamat S1, Brewer K1,
Bullano M1, Telly T2, Williamson T2
1 HealthCore, Inc, Wilmington, DE, USA; 2
Yamanouchi Pharma America, Inc, Paramus, NJ, USA |
|
PUK2 |
THE COST-EFFECTIVENESS OF SUBSTITUTING
DARBAPOETIN FOR EPOETIN: WHEN ECONOMIC MODELLING DOES NOT PREDICT REAL
LIFE RESULTS
Basskin LE
North Shore Medical Center, Cooper City, FL, USA |
|
PUK3 |
AN ECONOMIC MODEL OF OVERACTIVE BLADDER TREATMENT
PERSISTENCE: TOLTERODINE ER COMPARED TO OXYBUTYNIN ER
Subedi P1, Jumadilova Z2, Perfetto EM3
1 University of Maryland School of Pharmacy, Baltimore, MD,
USA; 2 Pfizer, Inc, New York, NY, USA; 3 The
Weinberg Group, Inc, Washington, DC, USA |
|
PUK4 |
A COMPARISON OF TOTAL DIRECT MEDICAL COSTS AMONG
PATIENTS RECEIVING AGENTS USED IN THE PHARMACOLOGIC MANAGEMENT OF
OVERACTIVE BLADDER
Harris HM1, Del Aguila MA1, Beaulieu JF1,
Boccuzzi SJ1, Jumadilova Z2, Wagner S3
1 Aetna Health Information Solutions, Blue Bell, PA, USA;
2 Pfizer, Inc, New York, NY, USA; 3 Pfizer, Inc,
Aubrey, TX, USA |
|
PUK5 |
ECONOMIC EVALUATION OF EVEROLIMUS WITH
REDUCED-DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT RECIPIENTS: AN
INTERNATIONAL PERSPECTIVE
Ethgen O1, Keown P2, Yang X3,
Ricci JF3, Spaepen E1, Annemans L1
1 IMS Health, Brussels, Belgium; 2 Vancouver
General Hospital, Vancouver, British Colombia, Canada; 3
Novartis Pharma AG, Basel, Switzerland |
|
PUK6 |
A PHARMACOECONOMIC EVALUATION OF OXYBUTYNIN AND
TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER
Ko Y, Malone DC, Armstrong EP
University of Arizona, Tucson, AZ, USA |
|
PUK7 |
ESTIMATING THE COST SAVINGS DUE TO THE EFFECT OF
KREMEZIN IN DELAYING THE ONSET OF RECEIVING DIALYSIS TREATMENTS AMONG
PATIENTS WITH CHRONIC RENAL FAILURE
Kang HY, Cho WH, Lee SM, Lee HY, Kim HJ, Moon YO
Yonsei University, Seoul, South Korea |
|
PUK8 |
THE DIRECT COSTS OF STRESS URINARY INCONTINENCE
TREATMENT AMONG WOMEN IN A MEDICAID POPULATION
Kinchen K1, Chang S2, Girts TK3,
Long S4, Pantos B1
1 Eli Lilly and Company, Indianapolis, IN, USA; 2
Medstat, Inc, Washington, DC, USA; 3 Boehringer Ingelheim
Pharmaceuticals, Ridgefield, CT, USA; 4 Medstat, Inc,
Hampden, ME, USA |
|
PUK9 |
INTERSTITIAL CYSTITIS COSTS, TREATMENT AND
COMORBIDITIES IN AN EMPLOYED POPULATION
Wu EQ1, Birnbaum H1, Parece A1,
Kang YJ1, Mareva MN1, Taitel H2
1 Analysis Group, Inc, Boston, MA, USA; 2
Ortho-McNeil Pharmaceuticals, Raritan, NJ, USA |
|
PUK10 |
EPOETIN ALFA AND DARBEPOETIN ALFA DOSING TRENDS
IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS
Mody S1, Padmanabhan V2, McKenzie S3,
Piech C4
1 Ortho Biotech Clinical Affairs LLC, Apex, NC, USA; 2
Ortho Biotech LP, Bridgewater, NJ, USA; 3 Ortho Biotech
Clinical Affairs LLC, Dallas, TX, USA; 4 Ortho Biotech
Clinical Affairs LLC, Bridgewater, NJ, USA |
|
PUK11 |
ADHERENCE TO EXTENDED RELEASE TOLTERODINE VERSUS
IMMEDIATE- AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED
PATIENTS WITH OVERACTIVE BLADDER
Ollendorf DA1, Jumadilova Z2,
Varadharajan S1, Girase P1
1 PharMetrics Inc, Watertown, MA, USA; 2 Pfizer,
Inc, New York, NY, USA |
|
PUK12 |
ADHERENCE WITH MEDICATIONS USED TO TREAT
OVERACTIVE BLADDER IN A MANAGED CARE POPULATION.
D'Angio RG1, Martinez LD1, Padilla M2,
Georgopopolus L3
1 Pfizer Inc, New York, NY, USA; 2 University of
New Mexico, Albuquerque, NM, USA; 3 Presbyterian Health
Plan, Albuquerque, NM, USA |
|
PUK13 |
PREDICTORS OF MEDICATION ADHERENCE AND ASSOCIATED
HEALTH CARE COSTS IN AN OLDER POPULATION WITH DETRUSOR OVERACTIVITY: A
LONGITUDINAL COHORT STUDY
Balkrishnan R1, Bhosle M1, Camacho F2,
Anderson RT2
1 Ohio State University, Columbus, OH, USA; 2
Wake Forest University School of Medicine, Winston Salem, NC, USA |
|
PUK14 |
FACTORS INFLUENCING THE ROUTE OF ADMINISTRATION
FOR EPOETIN TREATMENT AMONG U.S. HEMODIALYSIS PATIENTS
Thamer M1, Zhang Y1, Stefanik K1,
Kaufman J2, Cotter DJ1
1 MTPPI, Bethesda, MD, USA; 2 VA Boston
Healthcare System, Boston, MA, USA |
|
PUK15 |
IMPACTS OF IMPLEMENTING CASE PAYMENT SYSEM TO
HEMODIALYSIS OF MEDICAL AID PATIENTS ON DIALYSIS FREQUENCIES AND
EXPENDITURE IN KOREA
Kang HY1, Kim HJ1, Lee SH2,
Shin SH3, Cho WH1
1 Yonsei University, Seoul, South Korea; 2
Health Insurance Review Agency, Seoul, South Korea; 3
Pochon CHA University, Seoungnam, Kyonggi-do, South Korea |
|
PUK16 |
DOSING PATTERNS OF ERYTHROPOIETIC AGENTS IN
ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
Duh MS1, Lefebvre P2, Gosselin A2,
Mody S3,
McKenzie S4, Piech CT5
1 Analysis Group Inc, Boston, MA, USA; 2 Groupe
d'Analyse, Ltee, Montreal, QC, Canada; 3 Ortho Biotech
Clinical Affairs LLC, Apex, NC, USA; 4 Ortho Biotech
Clinical Affairs LLC, Dallas, TX, USA; 5 Ortho Biotech
Clinical Affairs LLC, Bridgewater, NJ, USA |
|
PUK17 |
PREVALENCE, DEMOGRAPHICS, AND PHARMACOLOGICAL
TREATMENT PATTERNS OF OVERACTIVE BLADDER IN A MANAGED CARE POPULATION
Daniel G1, Kamat S1, Brewer K1,
Bullano M1, Telly T2, Williamson T2
1 HealthCore, Inc, Wilmington, DE, USA; 2
Yamanouchi Pharma America, Inc, Paramus, NJ, USA |
|
PUK18 |
EVALUATION OF THE RELIABILITY AND VALIDITY OF THE
INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE (I-QOL) IN PATIENTS WITH
DETRUSOR HYPERREFLEXIA
Barron R1, Slaton T2, Kozma C3,
Reese P4
1 Allergan Corp, Irvine, CA, USA; 2 Independent
Consulant, West Columbia, SC, USA; 3 Independent
Consultant, West Columbia, SC, USA; 4 Reese and Associates,
Cary, NC, USA |
|
PUK19 |
ESTABLISHING THE CONTENT VALIDITY OF THE URINARY
SENSATION SCALE (USS)
Brewster JL1, Guan Z2, Green HL1,
Jumadilova Z2, Coyne KS1
1 MEDTAP International, Inc, Bethesda, MD, USA; 2
Pfizer, Inc, New York, NY, USA |
|
PUK20 |
PATIENT SELECTION CRITERIA IMPACTS OUTCOMES IN A
RETROSPECTIVE OAB STUDY
Del Aguila MA1, Harris HM1, Beaulieu JF1,
Boccuzzi SJ1, Jumadilova Z2, Wagner S3
1 Aetna Health Information Solutions, Blue Bell, PA, USA;
2 Pfizer, Inc, New York, NY, USA; 3 Pfizer, Inc,
Aubrey, TX, USA |
|
PUK21 |
DEGREE OF SYMPTOM BOTHER IN URINARY INCONTINENCE
Girts TK1, Fultz N2, Sternfeld B3,
Pohl G4, Kinchen K4
1 Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT,
USA; 2 University of Michigan, Ann Arbor, MI, USA; 3
Kaiser Permanente, Oakland, CA, USA; 4 Eli Lilly and
Company, Indianapolis, IN, USA |
|
